AU706008B2 - Inhibitors of farnesyl-protein transferase - Google Patents

Inhibitors of farnesyl-protein transferase Download PDF

Info

Publication number
AU706008B2
AU706008B2 AU53701/96A AU5370196A AU706008B2 AU 706008 B2 AU706008 B2 AU 706008B2 AU 53701/96 A AU53701/96 A AU 53701/96A AU 5370196 A AU5370196 A AU 5370196A AU 706008 B2 AU706008 B2 AU 706008B2
Authority
AU
Australia
Prior art keywords
hydrogen
alkyl
aryl
substituted
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU53701/96A
Other versions
AU5370196A (en
Inventor
Terrence M. Ciccarone
Suzanne C. Mactough
Theresa M. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/412,830 external-priority patent/US5534537A/en
Priority claimed from US08/413,137 external-priority patent/US5578629A/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU5370196A publication Critical patent/AU5370196A/en
Application granted granted Critical
Publication of AU706008B2 publication Critical patent/AU706008B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton

Description

WO 96/30015 PCT/US96/03980 -1- TITLE OF THE INVENTION INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE BACKGROUND OF THE INVENTION The Ras protein is part of a signalling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation. Biological and biochemical studies of Ras action indicate that Ras functions like a G-regulatory protein. In the inactive state, Ras is bound to GDP. Upon growth factor receptor activation Ras is induced to exchange GDP for GTP and undergoes a conformational change. The GTP-bound form of Ras propagates the growth stimulatory signal until the signal is terminated by the intrinsic GTPase activity of Ras, which returns the protein to its inactive GDP bound form Lowy and D.M.
Willumsen, Ann. Rev. Biochem. 62:851-891 (1993)). Mutated ras genes are found in many human cancers, including colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias. The protein products of these genes are defective in their GTPase activity and constitutively transmit a growth stimulatory signal.
Ras must be localized to the plasma membrane for both normal and oncogenic functions. At least 3 post-translational modifications are involved with Ras membrane localization, and all 3 modifications occur at the C-terminus of Ras. The Ras C-terminus contains a sequence motif termed a "CAAX" or "Cys-Aaal-Aaa 2 -Xaa" box (Cys is cysteine, Aaa is an aliphatic amino acid, the Xaa is any amino acid) (Willumsen et al., Nature 310:583-586 (1984)). Depending on the specific sequence, this motif serves as a signal sequence for the enzymes farnesyl-protein transferase or geranylgeranyl-protein transferase, which catalyze the alkylation of the cysteine residue of the CAAX motif with a or C20 isoprenoid, respectively. Clarke., Ann. Rev. Biochem.
,61:355-386 (1992); W.R. Schafer and J. Rine, Ann. Rev. Genetics 30:209-237 (1992)). The Ras protein is one of several proteins that are known to undergo post-translational farnesylation. Other farnesylated proteins.include the Ras-related GTP-binding proteins such as Rho, fungal mating factors, the nuclear lamins, and the gamma subunit of WO 96/30015 PCTIUS96/03980 -2transducin. James, et al., J. Biol. Chem. 269, 14182 (1994) have identified a peroxisome associated protein Pxf which is also farnesylated.
James, et al., have also suggested that there are farnesylated proteins of unknown structure and function in addition to those listed above Inhibition of famesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar and to modify other aspects of their transformed phenotype. It has also been demonstrated that certain inhibitors of famesyl-protein transferase selectively block the processing of the Ras oncoprotein intracellularly Kohl et al., Science, 260:1934-1937 (1993) and G.L. James et al., Science, 260:1937-1942 (1993). Recently, it has been shown that an inhibitor of farnesyl-protein transferase blocks the growth of rasdependent tumors in nude mice Kohl et al., Proc. Natl. Acad. Sci 91:9141-9145 (1994).
Indirect inhibition of farnesyl-protein transferase in vivo has been demonstrated with lovastatin (Merck Co., Rahway, NJ) and compactin (Hancock et al., ibid; Casey et al., ibid; Schafer et al., Science 245:379 (1989)). These drugs inhibit HMG-CoA reductase, the rate limiting enzyme for the production of polyisoprenoids including farnesyl pyrophosphate. Farnesyl-protein transferase utilizes farnesyl pyrophosphate to covalently modify the Cys thiol group of the Ras CAAX box with a farnesyl group (Reiss et al., Cell, 62:81-88 (1990); Schaber et al., J. Biol. Chem., 265:14701-14704 (1990); Schafer et al., Science, 249:1133-1139 (1990); Manne et al., Proc. Natl. Acad. Sci USA, 87:7541-7545 (1990)). Inhibition of farnesyl pyrophosphate biosynthesis by inhibiting HMG-CoA reductase blocks Ras membrane localization in cultured cells. However, direct inhibition of farnesyl-protein transferase would be more specific and attended by fewer side effects than would occur with the required dose of a general inhibitor of isoprene biosynthesis.
Inhibitors of farnesyl-protein transferase (FPTase) have been described in two general classes. The first are analogs of farnesyl diphosphate (FPP), while the second class of inhibitors is related to the protein substrates Ras) for the enzyme. In the peptide derived class WO 96/30015 PCT/US96/03980 -3of inhibitors, a subclass of inhibitors has been described which generally comprises cysteine containing molecules that are related to the CAAX motif that is the signal for protein prenylation. (Schaber et al., ibid; Reiss et. al., ibid; Reiss et al., PNAS, 88:732-736 (1991)). Such inhibitors may inhibit protein prenylation while serving as alternate substrates for the farnesyl-protein transferase enzyme, or may be purely competitive inhibitors Patent 5,141,851, University of Texas; N.E. Kohl et al., Science, 260:1934-1937 (1993); Graham, et al., J. Med. Chem., 37, 725 (1994)). In general, deletion of the thiol from a peptidyl CAAX derivative has been shown to dramatically reduce the inhibitory potency of the compound. However, the thiol group potentially places limitations on the therapeutic application of FPTase inhibitors with respect to pharmacokinetics, pharmacodynamics and toxicity. Therefore, a functional replacement for the thiol is desirable. With the exception of a group of antibiotics known as the pepticinnamins (Omura, et al., J.
Antibiotics 46:222 (1993)), non-thiol FPTase inhibitors that are competitive with the Ras substrate have not been described.
Another subclass of the peptide derived inhibitors which comprises peptidomimetic compounds wherein the central AA portion of the CAAX motif has been replaced by 3-aminobenzoic acid and 3aminomethylbenzoic acid spacers has recently been described Nigam et al. J. Biol. Chem., 268:20695-20698 (1993), Y. Qian et al. J. Biol.
Chem., 269:12410-12413 (1994)). FPTase peptidomimetic inhibitors further lacking a C-terminus peptidyl moiety (wherein the X peptide has been replaced by a non-peptide moiety) have also been recently described Vogt et al. J. Biol.Chem., 270:660-664 (1995)). All of the compounds in this second subclass of peptide derived inhibitors retain the thiol moiety.
It is, therefore, an object of this invention to develop nonpeptide compounds that do not have a thiol moiety, and that will inhibit farnesyl-protein transferase and thus, the post-translational farnesylation of proteins. It is a further object of this invention to develop chemotherapeutic compositions containing the compounds of this invention and methods for producing the compounds of this invention.
WO 96/30015 PCT/US96/03980 -4- SUMMARY OF THE INVENTION The present invention includes substituted aminoalkylbenzamide and aminobenzamide analogs which inhibit the faresyl-protein transferase, chemotherapeutic compositions containing the compounds of this invention, and methods for producing the compounds of this invention. Furthermore these analogs differ from those previously described as inhibitors of faresyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity.
WO 96/30015 PCT/US96/03980 The compounds of this invention are illustrated by the formulae: R4 R N (CRlb 2
)P'
N (CRlb 2 )p
R
5
-OR
6 R4
N-
R
5 R4 Rs/N
.OH
R
2 b DETAILED DESCRIPTION OF THE INVENTION The compounds of this invention are useful in the inhibition of farnesyl-protein transferase and the farnesylation of certain proteins.
WO 96/30015 WO 9630015PCT/US96/03980 -6- In a first embodiment of this invention, the farnesyl-protein transferase inhibitors are illustrated by the formula I: z R 3 a R 3 b RN
OH
H
IR
2 a R 2 b wherein: Ria and Rib are independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, R 1 0 0-,
R
1 1 RiOC(O)NRIO-, CN, N02, (RlO)2N-C(NRiO)-, RiOC(O)-, RlO0C(O)-, N3, -N(RIO)2, or Ri iOC(O)NRIO-, c) C1-C6 alkyl unsubstituted or substituted by aryl, heterocyclic, cycloalkyl, alkenyl, alkynyl, R100-, RiOC(O)-, RI0OC(O)-, N3, -N(RiO)2, or RI 1 0C(O)- R2a and R2b are independently selected from: a) hydrogen, b) C 1-C6 alkyl unsubstituted. or substituted by aikenyl, R 1 0 0-,
R
1 iS(O)mr, RiOC(O)NRIO-, CN, N3, (RlO)2N-C(NRiO)-, RIOC(O)-, RiOOC(O)-, -N(RiO)2, or RI IOC(O)NRiO-, c) aryl, heterocycle, cycloalkyl, alkenyl,
R
1 1 RiOC(O)NRi0-, CN, N02, (RI O)2N-C(NR 1 Ri R 1 OOC(O)-, N3, -N(RO)2,or R 1 OC(O)NRO-, and d) C I-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3-CiO cycloalkyl; WO 96/30015 WO 9630015PCT/US96/03980 -7- R3a and R3b are independently selected from: a) a side chain of a naturally occurring amino acid, b) an oxidized form of a side chain of a naturally occurring amino acid which is: i) methionine sulfoxide, or ii) methionine sulfone, and c) substituted or unsubstituted C I-C20 alkyl, C2-C20 alkenyl, C3-C1O cycloalkyl, aryl. or heterocyclic group, wherein the substituent is selected from F, Cl, Br, N(Rl 1 N02, R 1 0 RI 1 Rl 0
C(O)NR
1 0-, CN, (R 10 )2N-C(NRIO)-, RIOC(O)-, RIO0C(O)-, N3,
-N(R
1 0
R
1 1 0C(O)NRIO- and C1-C20 alkyl, and d) C I -C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C3- Cio cycloalkyl; or R3a and R3b are combined to form (CH2)s wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, S(O)m, and
R
4 and R5 are independently selected from: a) hydrogen, and b) (R )r (RB
Z
V Al(CRla 2 (CRla 2 kW/(CR b 2
R
7 is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, alkenyl, ailkynyl, perfluoroalkyl, F, Cl, Br, RIO0-, R 1 1 S(O)m-,
R
1 OC(0)NR 1 CN, N02, R' 0 2N-C(NR 1 Oy., R 1 OC(0)-, RIOOC(0)-, N3, -N(R 1 0 or RI IOC(0)NRIO-, and WO 96130015 WO 9630015PCT/US96/03980 -8- C) C 1-C6 alkyl. unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R 1 0 Rl 1 Rl 0 C(O)NH-, CN, H2N- Rl 0 R1 0 N3, -N(R 1 0 or
RIOOC(O)NH-;
R8 is selected from: a) hydrogen, b) alkenyl, alkynyl, periluoroalkyl, F, Cl, Br, R 1 0 0-, Rl 1 Rl 0
C(O)NR
1 CN, N02, (R'O)2N-C-(NR R 1 R 10 N3, 102,or R1 1 0C(O)NR 10-, and c) C1I-C6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R 1 0 RIIS(O)m-, Rl 0 C(O)NR1 0
CN,
(RIO)2N-C(NR 1 R 1 0
R
10 N3, -N(Rl 0)2, or R 1
IOC(O)NRIO-;
R 10 is independently selected from hydrogen, Cl1-C6 alkyl, benzyl and aryl; R I is independently selected from C 1-C6 alkyl and aryl; Al and A 2 are independently selected from: a bond, -CH=CH-, -C(O)NR10-, -NRl 0 0, -N(R 1 -S(0)2N(Rl 0 -N(RlO)S(0)2-, or S(O)m; V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) ClI -C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C2-C20 alkenyl, WO 96/30015 PCT/US96/03980 -9provided that V is not hydrogen if Al is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; Z is independently H2 or O; m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; pis 0,1,2, 3 or 4; r is 0 to 5, provided that r is 0 when V is hydrogen; sis 4 or 5; and uis 0or 1; or the pharmaceutically acceptable salts thereof.
In a second embodiment of this invention the prodrugs of compounds of formula I are illustrated by the formula II: Z R 3 a R3b
R
4 OR 6 N N-(CRb2)p H
R
5 H O R2a
R
2 b
II
wherein: Rla and Rib are independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, R100-,
R
1 1
R
1 0
C(O)NR
10 CN, N02, (R10)2N-C(NR10)-, R 10 R10OC(O)-, N3, -N(R 1 0)2, or R 1 1OC(0)NR 10 c) C1-C6 alkyl unsubstituted or substituted by aryl, heterocyclic, cycloalkyl, alkenyl, alkynyl, R 10 0-, WO 96/30015 WO 9630015PCTIUS96/03980
R
11
R
1
OC(O)NR
1 CN, (R 10 )2N-C(NRl RlOC(O)-, RIO0C(O)-, N3, -N(R 1 0 or R1 I0C(O)- R2a and R2b are independently selected from: a) hydrogen, b) C I-C6 alkyl unsubstituted. or substituted by aikenyl, R 100-,
R
11 Rl 0
C(O)NR
1 CN, N3, (Rl 0 )2N-C(NR RIOC(O)-, RlOOC(O)-, -N(R 1 0 or RI IOC(O)NRIO-, c) aryl, heterocycle, cycloalkyl, alkenyl, RIO0-,
R
1 1 Rl 0 C(O)NRIO-, CN, N02, (R 1 0 )2N-
R
1 RlOOC(O)-, N3, -N(R 1 0 )2, or R1 1 0C(O)NR 1 and d) C1-C6 alkyl. substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3- CG1 cycloalkyl; R3a and R3b are independently selected from: a) a side chain of a naturally occurring amino acid, b) an oxidized form of a side chain of a naturally occurring amino acid which is: i) methionine sulfoxide, or ii) methionine sulfone, and c) substituted or unsubstituted Ci1 -C20 alkyl, C2-C20 alkenyl, C3-C10 cycloalkyl, aryl. or heterocyclic group, wherein the substituent is selected from F, Cl, Br, N(RIO)2, N02, R 1 0 RI 1 RIOC(O)NRlO-, CN, (Rl 0 )2N-C(NR 10 RlOC(O)-, RO 0 N3, -N(Rl 0 Rl lOC(O)NRlO- and C1-C20 alkyl, and d) C1I-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C3- CIO cycloalkyl; or R3a and R3b are combined to form (CI1 2 wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, S(O)m, and
R
4 and R 5 are independently selected from: a) hydrogen, and b) 8) Z I I la 2 a I lb V-A (CR 2 )nA2(CR 2) W ti_4CR 2)p
R
6 is a) substituted or unsubstituted C 1
-C
8 alkyl or substituted or unsubstituted. C 5
-C
8 cycloalkyl, wherein the substituent on the alkyl is selected from: 1) aryl, 2) heterocycle, 3) -N(Rll) 2 4) -OR 0 or b) R12 0 *0 R 1
R
7 is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, periluoroalkyl, F, Cl, Br, RIOO0, R 11
RIOC(O)NR
10 CN, NO 2
R
10 2
NC(NR'
0
R'
0
R
10
N
3
-N(R
10 2 or RII0C(O)NRIO-, and C) CI-C 6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R' 0
R
11 Rl 0
C(O)NH-,
CN, H 2
N-
[N:\LIBAA]O1 556:TAB WO 96/30015 WO 9630015PCTfUS96/03980 -12- Rl 0
R
1 0 N3, -N(Rl 0 or
R
1
OOC(O)NH-;
R8 is selected from: a) hydrogen, b) alkenyl, alkynyl, peffluoroalkyl, F, Cl, Br, R100-,
R
1 1 RIOC(O)NRIO-, CN, N02, (Rl 0 )2N-C-(NR R lOC(O)-, R 1 OOC(O)-, N3, 102,or R1 1 0C(O)NR 10-, and c) C1I-C6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R 1 0 Rl IS(O)m-, Rl 0 C(O)NRIO-, CN, (Ri 0 )2N-C(NR 1 RI R N3, -N(Rl 0)2, or R 10 is independently selected from hydrogen, C1I-C6 alkyl, benzyl and aryl; R 11 is independently selected from C1I-C6 alkyl and aryl; R 12 is independently selected from hydrogen and C 1-C6 alkyl; R 13 is independently selected from Ci1-C6 alkyl; Al and A 2 are independently selected from: a bond, -CH=CH-, -CE-C-, -C(O)NR10-, -NRIOC(O)-, 0, -N(Rl 0 -S(0)2N(Rl 0 -N(RI 0 or S(O)m; V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C I -C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom, selected from 0, S, and N, and e) C2-C20 alkenyl, WO 96/30015 W096/0015PCTIUS96/03980 13 provided that V is not hydrogen if Al is S(O)m and V is not hydrogen if
A
1 l is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; Z is independently H2 or 0; m is n is p is r is s is u is 0, 1 or 2; 0, 1, 2, 3 or 4; 0, 1, 2, 3or 4; 0 to 5, provided that r is 0 when V is hydrogen; 4 or 5; and 0Oorl1; or the pharmaceutically acceptable salts thereof.
In a third embodiment of this invention, the inhibitors of farnesyl transferase are illustrated by the fonmula III:
HOCH
2
(CH
2 )q z L OH N (CR Ib, R 2 a/ R 2 b wherein: Ria and Rib are independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, R100-, Rl 1 Rl 0 C(0)NR 1 0 CN, N02, (RlO)2N-C(NR 1 RIOC(O)-, R10OC(0)-, N3, -N(Rl 0 )2, or RI IOC(0)NR 1 0-, WO 96/30015 WO 9630015PCT/US96103980 -14c) C1I-C6 alkyl. unsubstituted or substituted by aryl, heterocyclic, cycloalkyl, alkenyl, alcynyl, R100-,
RI
1 Rl 0
C(O)NR
10 CN, (Rl 0 )2N-C(NR 1 RlOC(O)-, R10OC(O)-, N3, -N(R 1 0 or Ri OC(O}- R2a and R2b are independently selected from: a) hydrogen, b) C 1-C6 alkyl unsubstituted or substituted by alkenyl, R 1 0 0-,
R
1 1
RIOC(O)NR
10 CN, N3, (Rlo)2N-C(NR 1 RlOC(O)-, RIOOC(O)-, -N(R 1 0 or R1 1OC(O)NR10-, c) aryl, heterocycle, cycloallcyl, alkenyl, R 1 0 0-,
R
1 1 Rl 0
C(O)NR
1 0 CN, N02, (Ri %2N-C(NR 1
R
1 Ri OOC(O)-, N3, -N(Rl 0 or R 1 1OC(O)NR10-, and d) CGI -C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3-ClO cycloalkyl;
R
4 and R5 are independently selected from: a) hydrogen, and b) V Al(CRla 2 2 (CRla 2 ~W (R'I 2p
R
7 is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R 10 R1 1 S(O)m-, CN, N02, R 10 2N-C(NR 1 0
RIOC(O)-,
RIO0C(O)-, N3, -N(RIO)2, or R1 1OC(O)NR10-, and WO096/30015 PCT/US96103980 c) C 1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, peffluoroalkyl, F, Cl, Br, R 10 R 1 1 R 1 C(O)NH-, CN, H2N-C(NH)-, RlOC(O)-, R 10 N3, -N(R 1 0 or
R
1
OOC(O)NH-;
R8 is selected from: a) hydrogen, b) alkenyl, alkynyl, peffluoroalkyl, F, Cl, Br, R 10 0-, RIIS(O)m-, Rl 0
C(O)NR
10 CN, N02, (Rl 0 )2N-C- (NRIO)-, RlOC(O)-, RIOOC(O)-, N3, -N(R 1 0 or
R
1 1OC(O)NR10-, and c) C 1-C6 alkyl unsubstituted or substituted by peffluoroalkyl, F, Cl, Br, R 10
R
1 1 RIOC(O)NRIO-, CN,
(R
10 )2N-C(NR 10 RlOC(O)-, RI OOC(O)-, N3, 0)2, or R1 1OC(O)NR10-; R 1 0 is independently selected from hydrogen, ClI-C6 alkyl, benzyl. and aryl; R 1 1 is independently selected from C 1-C6 alkyl. and aryl; Al and A 2 are independently selected from: a bond, -CH=CH-, -CZRC-, -C(O)NRIO-, -NR 1 0, -N(Ri -S(0)2N(Rl 0 -N(Rl 0 or S(O)m; V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C I -C20 ailkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C2-C20 alkenyl, WO 96/30015 PCT/US96/03980 -16provided that V is not hydrogen if Al is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; Z is independently H2 or O; m is n is pis q is r is s is u is 0, 1 or 2; 0, 1, 2, 3 or 4; 0, 1, 2, 3 or 4; 0, 1 or 2; 0 to 5, provided that r is 0 when V is hydrogen; 4 or 5; and 0 or 1; or the pharmaceutically acceptable salts thereof.
In a fourth embodiment of this invention the prodrugs of compounds of formula III are illustrated by the formula IV: Z q /N (CR 1 H O 2a R 2 b wherein: R1a and Rib are independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, R 10 0-,
R
11
R
10 C(O)NR10-, CN, N02,
(R
10 )2N-C(NR10)-, R10C(0)-, R10OC(O)-, N3, -N(R 10 )2, or R 1 1 OC(0)NR10-, WO 96/30015 WO 9630015PCTIUS96Io39rnj 17 c) C I-C6 alkyl unsubstituted or substituted by aryl, heterocyclic, cycloalicyl, alkenyl, alkynyl, R 1 0 0-,
R
1 1 R' OC(O)NR 1 CN, (R 10 )2N-C(NR 1 Rl 0
R
1 0 N3, or RI I0C(O)-
NI-
R2a and R2b are independently selected from: a) hydrogen, b) C 1-C6 alkyl unsubstituted or substituted by alkenyl, R 1 0 0-, Rl 1 Rl 0 C(O)NR10-, CN, N3, (R' 0 )2N-C(NR10)-, RlOC(O)-, R 1 0 -N(Rl 0 or RI 1
OC(O)NR
1 0-, c) aryl, heterocycle, cycloalkyl, alkenyl, RIO0-,
R
1 1 Rl 0
C(O)NR
10 CN, N02, (RI 0 )2N-C(NR' R lOC(O)-, R' 0 N3, -N(Rlo)2, or RI 1 OC(O)NR10-, and d) Ci1 -C6 ailkyl substituted with an unsubstituted. or substituted group selected from aryl, heterocyclic and C3-ClO cycloalkyl;
R
4 and R5 are independently selected from: a) hydrogen, and b) V Al(CRla 2 )nA ROW- (la 2 ib)
R
7 is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, alkenyl, aikynyl, perfluoroalkyl, F, Cl, Br, R 100-, R I 1 RI OC(O)NR 1 CN, N02, R 1 0 2N-C(NR 1 0Oy., R 1
OC(O)-,
R10OC(O)-, N3, -N(Rl 0 or RI 1 0C(O)NR10-, and c) C1I-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloallcyl, alkenyl, alkynyl, perfluoroalkyl, F, WO 96/30015 PCTIUS96/0398rj -18- Cl, Br, RIO0-, Rl 1 RIOC(O)NH-, CN, H2N- RIOC(O)-, RIO0C(O)-, N3, -N(RlO)2, or RIO0C(O)NH-; R8 is selected from: a) hydrogen, b) alkenyl, alkynyl, perfluoroalcyl, F, Cl, Br, R 1 0 0-, RI IS(O)m-, Rl 0 C(O)NRIO-, CN, N02, (RI 0 )2N-C-(NRl Ri RI 0 N3, -N(R 10)2, or R I IOC(O)NR 10-, and C) ClI-C6 ailkyl unsubstituted or substituted by peffluoroalkyl, F, Cl, Br, R 100-, R I 1 R IOC(O)NRl10-,
CN,
(RI 0 )2N-C(NRl R 0 Rl 0 N3, -N(Rl 0)2, or RI IOC(O)NRIO-; R 10 is independently selected from hydrogen, C I -C6 alkyl, benzyl and aryl; R 11 is independently selected from C 1-C6 alkyl and aryl;
A
1 I and A 2 are independently selected from: a bond, -CN=CH-,
-C-ZC-,
-C(O)NR10-, -NRlOC(O)-, 0, -N(RIO)-, -S(0)2N(R -N(Rl 0 Or S(O)m; V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C I -C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom. selected from 0, S, and N, and e) C2-C20 ailkenyl, provided that V is not hydrogen if Al is S(O)m and V is not hydrogen if AlI is a bond, n is 0 and A 2 is S (O)m; I WO 96130015 PCT/US96/03980 -19- W is a heterocycle; Z is independently H2 or O; mis n is p is q is r is sis u is 0, 1 or 2; 0, 1, 2, 3 or 4; 0, 1, 2, 3 or 4; 0, 1 or 2; 0 to 5, provided that r is 0 when V is hydrogen; 4 or 5; and 0 or 1; or the pharmaceutically acceptable salts thereof.
In a more preferred embodiment of this invention, the Ras farnesyl transferase inhibitors are illustrated by the Formula Ia:
R
4 (CR1b2) p wherein: Ria is independently selected from: hydrogen or C1-C6 alkyl; Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10
-N(R
10 )2 or alkenyl, c) C -C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, R 10 or -N(R10)2; R2a is selected from: a) hydrogen, WO 96/30015 WO 9630015PCTfUS96/03980 b) C I -C6 alkyl unsubstituted or substituted by alkenyl, R 100., RI 1 RIOC(0)NR10-, CN, N3, (RIO)2N-C(NRlO)-, RIOC(0)-, R 1 0 or Rl I0C(0)NR 1 0-, c) aryl, heterocycle, cycloalkyl, alkenyl, R 10 0-, RI 1 Rl 0 C(0)NRIO-, CN, N02, (R 1 0 )2N-C(NR R lOC(0)-, RI 0 N3, -N(RO)2,or RI IOC(0)NRIO-, and d) C1I-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3- C 1 cycloallcyl; R2b is hydrogen; R3a and R3b are independently selected from: a) a side chain of a naturally occurring amino acid, b) an oxidized form of a side chain of a naturally occurrng amino acid which is: i) methionine sulfoxide, or ii) methionine sulfone, c) substituted or unsubstituted Ci1-Ci1 alkyl, C2-C 10 alkenyl, C3-CIO cycloalicyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, N02, R 10
R
1 IS(0)m-, Rl 0 C(0)NRIO-, CN, (R 1 %2N-C(NRl R 1 0
R
1 0 N3, -N(R 10 R I I0C(0)NR 10- and Cl1-C20 alkyl, and d) Cl-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C3- Clo cycloalkyl;
R
4 and R5 are independently selected from: a) hydrogen, and WO 96/30015 WO 9630015PCT/US96O3980 -21- (R )r (R8' z I(
U
R7 is independently selected from: a) hydrogen, b) ClI-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C 1-C6 perfluoroalkyl, F, Cl, R 1 0 RlOC(O)NRIO-, CN, N02, (Rl 0 )2N-C(NR 1 Rl 0 R 10
-N(R
1 0 or R11OC(O)NR 1 and c) Cl-C6 alkyl substituted by Cl-C6 peffluoroalkyl, R100-, RlOC(O)NR 1 (Rl 0 )2N-C(NR 1 RlOC(O)-,
R
1 0
-N(R
1 0 or R 1 1OC(O)NRIO-;,
R
8 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, Cl1 -C6 perfluoroalkyl, F, Cl,
R
10 Rl 1
RIOC(O)NRI
0 CN, N02, (R 10 )2N-C(NR 1 Ri R 1 0 -N(Rl 0)2, or RI I0C(O)NRIO-, and c) C 1-C6 alkyl unsubstituted or substituted by C 1-C6 perfluoroalkyl, F, Cl, R 1 0 R1 1 R 1 C(O)NR 10 CN, (R 10 )2N-C(NR 1 RlOC(O)-, Ri OOC(O)-, -N(Rl 0)2, or R 1 R 10 is independently selected from hydrogen, ClI-C6 alkyl, benzyl and aryl; R 11 is independently selected from ClI-C6 alkyl and aryl; A I and A 2 are independently selected from: a bond, -CH=CH-, -C(O)NR10-, 0, or S(O)m; V is selected from: WO 96/30015 PCT/US96/03980 22a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C -C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if Al is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or isoquinolinyl; Z is independently H2 or O; mis 0, 1 or 2; n is 0, 1, 2, 3 or 4; pis 0,1, 2, 3 or 4; r is 0 to 5, provided that r is 0 when V is hydrogen; and uis 0or 1; or the pharmaceutically acceptable salts thereof.
In a second more preferred embodiment of this invention, the prodrugs of the preferred compounds of Formula I are illustrated by the Formula IIa:
R
4 Z R3a R3b N- (CRlb 2 )p
OR
R
5
N
R
2 b WO 96/30015 PCTfIJS96O39Scj 23 R Ia is independently selected from: hydrogen or C1I-C6 alkyl; RlIb is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, RIO0-, -N(R'O)2 or alkenyl, C) Cl1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, RIO0-, or -N(RlO)2; R2a is selected from: a) hydrogen, b) C 1-C6 alkyl unsubstituted or substituted by alkenyl, R 1 0 0-,
R
1 1 RIOC(O)NR10-, CN, N3, (RIO)2N-C(NRlO)-, RlOC(O)-, RIO0C(O)-,
-N(R
1 0 or RI 1 0C(O)NRIO-, c) aryl, heterocycle, cycloalkyl, alkenyl, RIO0-, RlS(O)m-, RIOC(O)NR10-, CN, N02, (R 10 )2N- C(NRIO)-, Rl 0
R
1 0 N3, -N(RlO)2, or R I I0C(O)NR 1 and d) ClI-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3- Cl1O cycloalkyl; R2b is hydrogen; R3a and R3b are independently selected from: a) a side chain of a naturally occurring amino acid, b) an oxidized form of a side chain of a naturally occurring amino acid which is: i) methionine sulfoxide, or ii) metbionine sulfone, c) substituted or unsubstituted C I-Cl1O alikyl, C2-C 10 alkenyl, C3-CIO cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, N02, R 1 0 R 1 1S(O)m-, R I C(O)NR 10-, CN, WO 96/30015 WO 9630015PCTIUS96/03980 -24- (Ri 0 )2N-C(NRIO)-, R 1 Ri OOC(O)-, N3, -N(R'1 0 R 1 OC(O)NR 1 0- and C 1-C20 ailkyl, and d) C1I-C6 alkyl. substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C3- C 10 cycloalkyl;
R
4 and R5 are independently selected from: a) hydrogen, and b) ~V -A A(CRla 2 (CRl) V I (CR b)/
R
6 is a) substituted or unsubstituted C1-C8 alkyl or substituted or unsubstituted C5-C8 cycloalkyl, wherein the substituent on the alkyl is selected from: 1) aryl, 2) heterocycle, 3) -N(R'1 1 )2, 4) -OR 10 or b)
R
2 0o R 0 1R 3 R7 is independently selected from: a) hydrogen, b) C 1-C6 alkyl, C2-C6 ailkenyl, C2-C6 alkynyl, C1I-C6 perfinoroalkyl, F, Cl, R 10 RIOC(O)NR10-, CN, N02,
(R
1 0 )2N-C(NR 1
R
1 0 R' 0 -N(Rl 0)2, or
RI
1 0C(O)NR 1 and C) C1I-C6 alkyl substituted by C1I-C6 perifuoroalkyl, R 10 0-,
R
1
OC(O)NR
1 (Rlo)2N-.C(NR1)., RI OC(O)-, RIOOC(O)-, -N(Rl 0 or RI 1 0C(O)NR10-, 4 WO 96/30015 W096/0015PCTfUS96/03980 25 R8 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, C1I-C6 peffluoroalkyl, F, Cl, RIO0-, RI IS(O)m-, Rl 0
C(O)NR
1 CN, N02,
(R
1 0 )2N-C(NRIO)-, RlOC(O)-, R 10 -N(Rl 0 or R11OC(O)NR10-, and c) C1I-C6 alkyl unsubstituted or substituted by C 1-C6 perfluoroalkyl, F, Cl, R 1 0 R I 1 R I C(O)NR CN, (R 1 0 )2N-C(NR 1 RlOC(O)-, R 10 -N(RlO)2, or R 1 R 10 is independently selected from hydrogen, C1I-C6 alkyl, benzyl and aryl; R I is independently selected from C I -C6 alkyl. and aryl;
R
12 is independently selected from hydrogen and C1I-C6 ailkyl; R 13 is independently selected from C1I-C6 alkyl;
A
1 l and A 2 are independently selected from: a bond, -CH=CH-, -CR-C-, -C(O)NR10-, 0, or S(O)m; V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C I -C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C2-C20 alkenyl, and WO 96/30015 PCTIUS96/03980 -26provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or isoquinolinyl; Z is independently H2 or O; mis n is p is r is u is 0, 1 or 2; 0, 1, 2, 3 or 4; 0, 1,2, 3 or4; 0 to 5, provided that r is 0 when V is hydrogen; and 0or 1; or the pharmaceutically acceptable salts thereof.
In a third more preferred embodiment of this invention, the inhibitors of farnesyl transferase are illustrated by the formula IIIa:
HOCH
2
(CH
2 )q R 4
Z
N-(CRlb 2 )p HN
OH
N
2 b R2a R2b Ilia wherein: Ra is independently selected from: hydrogen or C1-C6 alkyl; Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10 -N(R10)2 or alkenyl, 4 WO 96130015 WO 9630015PCT1US96/03980 27 C) C1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, RIO0-, or -N(R 1 0 )2; R2a is selected from: a) hydrogen, b) C I -C6 alkyl unsubstituted or substituted by alkenyl, R 1 00., Rl 0
R
10
-N(R
1 0 or R 1 IOC(0)NR 1 0-, c) aryl, heterocycle, cycloalkyl, alkenyl, R 10 0-,
R
1 1 Rl 0 C(0)NR 1 CN, N02, (Rl 0 )2N- Rl 0
R
1 0 N3, -N(RlO)2, or Ri 11OC(0)NR 10-, and d) Ci1 -C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3- Cio cycloalkyl; R2b is hydrogen;
R
4 and R5 are independently selected from: a) hydrogen, and b) (R 7r (R 8 z V Al(CRla 2 (CRlOn W (CRib) A
R
7 is independently selected from: a) hydrogen, b) Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 peffluoroalkyl, F, Cl, RIO0-, RIOC(0)NRiO-, CN, N02, (RI 0 )2N-C(NR RI Ri OOC(0)-, -N(RI 0)2, or
R
1 1 0C(0)NR 1 and c) C I-C6 alkyl substituted by C I-C6 perfluoroalkyl, R 10 0-, R iOC(0)NRI (Ri 0 )2N-C(NR 1 R iOC(0)-, RIOOC(0)-, -N(RIO)2, or R 1 WO 96/30015 WO 9630015PCTIUS96/03980 -28 R8 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, ClI-C6 peffluoroalkyl, F, Cl,
R
1 0
R
1 1 S(O)m-r, RIOC(O)NRIO-, CN, N02, (Ri 0 )2N-C(NR Rl Rl 0 -N(Rl 0)2, or RI 1OC(O)NRIO-, and c) Cl1-C6 ailkyl unsubstituted or substituted by ClI-C6 peffluoroalkyl, F, Cl, R 1 0 RI IS(O)m-, RIOC(O)NRIO-, CN, (RIO)2N-C(NR 10 RlOC(O)-, RIOOC(O)-, -N(R'O)2, or RI R 1 0 is independently selected from hydrogen, ClI-C6 alkyl, benzyl and aryl; R 1 1 is independently selected from C I -C6 ailkyl and aryl;
A
1 l and A 2 are independently selected from: a bond, -CH=CH-, -CR-C-, -C(O)NR10-, 0, or S(O)m; V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C I -C20 alkyl. wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if A 1 l is S(O)m and V is not hydrogen if
A
1 is a bond, n is 0 and A 2 is S(O)m; WO 96/30015 PCT/US96/03980 -29- W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or isoquinolinyl; Z is independently H2 or O; mis n is p is qis r is u is 0, 1 or 2; 0, 1, 2, 3 or 4; 0, 1, 2, 3 or 4; 0, 1 or 2; 0 to 5, provided that r is 0 when V is hydrogen; and 0 or 1; or the pharmaceutically acceptable salts thereof.
In a fourth more preferred embodiment of this invention, the prodrugs of the preferred compounds of Formula II are illustrated by the Formula IVa:
RN
R
2 b IVa wherein: Rla is independently selected from: hydrogen or C1-C6 alkyl; Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10
-N(R
10 )2 or alkenyl, c) C1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, R 10 or -N(R 10 )2; WO 96/30015 WO 9630015PCTfUS96/03980 30 R2a is selected from: a) hydrogen, b) C1I-C6 alkyl unsubstituted or substituted by alkenyl, R 10 0-,
R
1 Rl 0 C(O)NRIO-, CN, N3, (Rl 0 )2N-C(NRIO)-, RIOC(O)-, R 10 -N(RIO)2, or RlI C(O)NRIO-, c) aryl, heterocycle, cycloalkyl, alkenyl, RIO0-, Rl 1 RIOC(O)NR10-, CN, N02,
(R
1 0 )2N-C(NRIO)-, RIOC(O)-, RIO0C(O)-, N3, -N(R 1 0 or RI 1OC(O)NRIO-, and d) C I-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3- Ci1G cycioailkyl; R2b is hydrogen;
R
4 and R5 are independently selected from: a) hydrogen, and b) (R )r R8z
V
7 i Al(CRla 2 2 Cl 2 R' Risindependently selected from: a) hydrogen, b) C1I-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C 1-C6 periluoroalkyl, F, Cl, RIOO-, Rl 0 C(O)NR10-, CN, N02, (RI 0 )2N-C(NR 1
R
1
R
1 0 -N(R 10)2, or R 1 0C(O)NR 10-, and C) C I-C6 alkyl substituted by Ci1-C6 peffluoroalcyl, R 10 0-, Ri OC(O)NRl (Rl 0 )2N..C(NRi R 1 0 R10OC(O)-, -N(Rl 0 or RI
R
8 is selected from: WO 96/30015 WO 9630015PCTfUS96/03980 -31a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, C1I-C6 perfluoroalkyl, F, Cl, RIO0-, R 1 1 RIOC(O)NRIO-, CN, N02, (Ri 0 )2N-C(NR 10 R 0 R 1 0 -N(Ri 0)2, or R11OC(O)NRIO-, and C) C I -C6 alkyl unsubstituted or substituted by C I -C6 perfluoroalcyl, F, Cl, R 1 0
R
1 IS(O)m-, R 1 C(O)NR CN, (Rl 0 )2N-C(NRIO)-, RIOC(O)-, RIO0C(O)-, -N(R 1 0 )2, or R 1
IOC(O)NRIO-;
R 10 is independently selected from hydrogen, C1I-C6 alkyl, benzyl and aryl; R 1 1 is independently selected from C 1-C6 ailkyl and aryl;
A
1 l and A 2 are independently selected from: a bond, -CH=CH-, -CR-C-, -C(O)NRIO-, 0, or S(O)m; V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) ClI -C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if
A
1 is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or isoquinolinyl; WO 96/30015 WO 96/00 15PCTIUS96/03980 32 Z is independently H2 or 0; m is 0,l1or 2; n is 0, 1, 2,3or 4; p is 0, 1,2, 3or 4; q is 0,l1or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; and u is 0Oorl1; or the pharmaceutically acceptable salts thereof.
The preferred compounds of this invention are as follows: 1(S)-carboxy-3-methylthiopropyl)-3-(4-imidazolylmethyl)aminomethylbenzamide N-(l1(S)-carbomethoxy-3-methylthiopropyl)-3-(4-imidazolylmethyl)aminomethylbenzamide 1(S)-carboxy-3 -methylthiopropyl)-3- [N,N-bis-(4-imnidazolemethyl)aminomethyl]benzamide 1 (S)-carbomethoxy-3-methylthiopropyl)-3-[N,N-bis-(4-imidazolemethyl)aminomethyl]benzamide 1(S)-carboxy-3-methylthiopropyl) 3-[(4-imidazolylmethyl) -Nmethylaminomethyllbenzamide N-(l1(S )-carbomethoxy-3-methylthiopropyl) 3- [4-imidazolylmethyl) -Nmethylaniinomethyllbenzamide N-(l1(S)-carboxy-3-methylthiopropyl) 4- [(4-imidazolylmethyl)amino]benzamide WO 96/30015 WO 9630915PCT/US96103980 33 1(S)-carbomethoxy-3-methylthiopropyl) 4-[(4-imidazolylmethyl)amino]benzamide 1(S)-carboxy-3-methylthiopropyl)-3-I(4-imidazolylmethyl) amino] benzamide 1 (S)-carbomethoxy-3-methylthiopropyl)-3- [(4-imidazolylmethyl) amino] benzamide 1 (S)-carbomethoxy-3-methylthiopropyl)-3-[(4-iniidazolylpropyl) amino]benzamide N-(l1(S)-Carboxy-3-methylthiopropyl)-3- [(4-imidazolyipropyl) amino] benzamide, 1 (S)-Carbomethoxy-3-methylthiopropyl)-3- imidazolylymethyl)-N-(4-nitrobenzyl)aminomethyl]benzamide 1(S)-Carboxy-3-methylthiopropyl)-3- [N-(4-imidazolylymethyl)-N-(4nitrobenzyl)aminomethyl]benzamide N-(l1(S)-carboxy-3-methylthiopropyl)-3- [N,N-bis-(4nitrophenylmethyl)] aminomethylbenzamide N-(l1(S)-carbomethoxy-3-methylthiopropyl)-3- [N,N-bis-(4nitrophenylmethyl)aminomethyl]benzamide or the pharmaceutically acceptable salts thereof.
Specific examples of the compounds of the invention are: 1(5)-carboxy-3-methylthiopropyl)-3- [N,N-bis-(4nitrophenylmethyl)aminomethyl]benzamide WO 96/300 15 PCT/US96/03Si80 34- 0 2
N
N-(l1(S)-carbomethoxy-3-methylluiopropyl..3.[N,N-bis-(4nitrophenylmethyl)aminomethyl]benzanmjde
H
3 C, s 0 2 NO 0 2
N
1 (S)-carboxy-3-methylthiopropyl)-3- [N,N-bis(4-iniidazolemethyl)aminomethyl] benzamide H3C, WO 96/30015 PTU9/38 PCTIUS96/03980 35 N-(l 1 rxmtox--ehlhopoy)3[,-bs4iiaoe methyl)aminomethyl] benzaniide
H
N,
H
3 Cd
HN,,
1(S)-Carboxy-3-methylffiopropyl)-3-[N(4iidazolylymethy1)..N(4nitrobenzyl)aminomethyl]benzamide H
H
3
C,
N s
N
7 0 N N O Ho 0 2
N
1 (S)-Carbomethoxy-3-methylthiopropyl..3.[N-(4imidazolylymethyl)-N-(4-nitrobenzy1)aminomethyl]benzamide
H
3
C,.
0 0 2
N
WO 96/30015 PCT/US96/03980 -36or the pharmaceutically acceptable salts thereof.
In the present invention, the amino acids which are disclosed are identified both by conventional 3 letter and single letter abbreviations as indicated below: Alanine Ala A Arginine Arg R Asparagine Asn N Aspartic acid Asp D Asparagine or Aspartic acid Asx
B
Cysteine Cys
C
Glutamine Gin
Q
Glutamic acid Glu E Glutamine or Glutamic acid Glx Z Glycine Gly
G
Histidine His H Isoleucine Ile I Leucine Leu L Lysine Lys
K
Methionine Met M Phenylalanine Phe F Proline Pro P Serine Ser S Threonine Thr T Tryptophan Trp W Tyrosine Tyr Y Valine Val V WO 96/30015 PCT/US96/03980 -37- The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention.
As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
As used herein, "cycloalkyl" is intended to include nonaromatic cyclic hydrocarbon groups having the specified number of carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
"Alkenyl" groups include those groups having the specified number of carbon atoms and having one or several double bonds.
Examples of alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, isoprenyl, farnesyl, geranyl, geranylgeranyl and the like.
As used herein, "aryl" is intended to include any stable monocyclic, bicyclic or tricyclic carbon ring(s) of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of aryl groups include phenyl, naphthyl, anthracenyl, biphenyl, tetrahydronaphthyl, indanyl, phenanthrenyl and the like.
The term heterocycle or heterocyclic, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 11membered bicyclic or stable 11-15 membered tricyclic heterocycle ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, 0, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, WO 96/30015 PCTJUS96/03980 -38benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isotbiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2 -oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, pyridonyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinolinyl N-oxide, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, and thienyl.
As used herein, the terms "substituted aryl", "substituted heterocycle" and "substituted cycloallcyl" are intended to include the cyclic group which is substituted with 1 or 2 substitutents selected from the group which includes but is not limited to F, Cl, Br, CF3, NH2, N(C 1-C6 alkYl)2, N02, CN, (C I-C6 allcyl)O-, -OH, (ClI-C6 alkyl)S (Cl -C6 alkyl)C(O)NH-, H2N-C(NH)-, (Ci -C6 alkyl)C(O)-, (C1-C6 alkyl)OC(O)-, N3,(Cl-C6 alkyl)OC(O)NH- and Cl-C20 alkyl.
When R 3 a and R3b are combined to formn (CH2)s cyclic moieties are formed. Examples of such cyclic moieties include, but are not limited to: WO 96/30015 PCT/US96/03980 -39- In addition, such cyclic moieties may optionally include a heteroatom(s). Examples of such heteroatom-containing cyclic moieties include, but are not limited to: 0 S0 0 S 0 H O 1
COR
10 The pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.
It is intended that the definition of any substituent or variable R10, Z, n, etc.) at a particular location in a molecule be independent of its definitions elsewhere in that molecule. Thus, -N(R10)2 represents -NHH, -NHCH3, -NHC2H5, etc. It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth below.
The pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention WO 96/30015 PCT/US96/03980 which contain a basic moiety by conventional chemical methods.
Generally, the salts are prepared by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.
The compounds of the invention can be synthesized from their constituent amino acids by conventional peptide synthesis techniques, and the additional methods described below. Standard methods of peptide synthesis are disclosed, for example, in the following works: Schroeder et al., "The Peptides", Vol. I, Academic Press 1965, or Bodanszky et al., "Peptide Synthesis", Interscience Publishers, 1966, or McOmie "Protective Groups in Organic Chemistry", Plenum Press, 1973, or Barany et al., "The Peptides: Analysis, Synthesis, Biology" 2, Chapter 1, Academic Press, 1980, or Stewart et al., "Solid Phase Peptide Synthesis", Second Edition, Pierce Chemical Company, 1984. The teachings of these works are hereby incorporated by reference.
Abbreviations used in the description of the chemistry and in the Examples that follow are: Ac20 Boc
DBU
DMAP
DME
DMF
EDC
HOBT
Et3N EtOAc
FAB
HOOBT
HPLC
MCPBA
Acetic anhydride; t-Butoxycarbonyl; 1,8-diazabicyclo[5.4.0]undec-7-ene; 4-Dimethylaminopyridine; 1,2-Dimethoxyethane; Dimethylformamide; 1-( 3 -dimethylaminopropyl)-3-ethyl-carbodiimidehydrochloride; 1-Hydroxybenzotriazole hydrate; Triethylamine; Ethyl acetate; Fast atom bombardment; 3-Hydroxy- 1,2,2-benzotriazin-4(3H)-one; High-performance liquid chromatography; m-Chloroperoxybenzoic acid; WO 96/30015 PCT/US96/03980 -41- MsCI NaHMDS Py
TFA
THF
Methanesulfonyl chloride; Sodium bis(trimethylsilyl)amide; Pyridine; Trifluoroacetic acid; Tetrahydrofuran.
Compounds of this invention are prepared by employing the reactions shown in the following Reaction Schemes A-J, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Some key bond-forming and peptide modifying reactions are: Reaction A Amide bond formation and subsequenmt generation of the amino methyl moiety using standard solution or solid phase methodologies.
Preparation of a reduced peptide subunit by reductive alkylation of an amine by an aldehyde using sodium cyanoborohydride or other reducing agents.
Reaction B Reaction C Alkylation of the amino moiety of the central phenyl ring.
Reaction D Peptide bond formation and protecting group cleavage using standard solution or solid phase methodologies.
These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to synthesize fragments which are subsequently joined by the alkylation reactions described in the Reaction Schemes.
WO 96/30015 WO 96/00 15PCT[US96O3980 -42- REACTION SCHEME A Reaction A. Coupling of residues to form an amide bond 0 1) NEt 3
CH
2
CI
2 2) LiN 3
DMSO
R 2 b 3) H 2 Pd/C MeOH
R
6 H 0
R
2 a' 'R 2 b WO 96/30015 PTU9I3S PCTfUS96/03980 -43- REACTION SCHEME B Reaction B. Preparation of reduced amino acid linkages by reductive alkylation 0 2 N 0H +HN)RO Na(OAC) 3 B3H Ra R 2 b 0 0 2 N N O 6 2) Fe, HOAc H H 0 RR~b
R
6 R~a'
.R
2 b WO 96130015 PCT1US96103980 -44- ,REACTION SCHEME C Reaction C. Alkylation of the amino moiet
H
2 N. R 4 XL NaH R 2 b 1) HCI, EtOAc 2) NaOH
H
R4N.
R
2
'R
2 b REACTION SCHEME D Reaction D. Coupling of residues to form an amide bond H0 ONy OH
H
2 N 0 R 2 a R 2 b 0 H0 O N 0HC 0 H 0
R
2 a R 2 b EDO, HOBT or HOOBT Et 3 N, DMF ~I or TFA where xL is a leaving group, Br-, I- or MsO-;.
WO 96/30015 PCTIUS96/03980 Reaction Schemes E M illustrate reactions wherein the non-sulfhydryl-containing moiety at the N-terminus of the compounds of the instant invention is attached to an aminomethylbenzamide subunit which may be further elaborated to provide the instant compounds.These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to synthesize fragments which are subsequently joined by the reactions described in Reaction Schemes A D.
The intermediates whose synthesis are illustrated in Reaction Schemes A D can be reductively alkylated with a variety of aldehydes, such as I, as shown in Reaction Scheme E. The aldehydes can be prepared by standard procedures, such as that described by O. P. Goel, U.
Krolls, M. Stier and S. Kesten in Organic Syntheses, 1988, 67, 69-75, from the appropriate amino acid (Reaction Scheme The reductive alkylation can be accomplished at pH 5-7 with a variety of reducing agents, such as sodium triacetoxyborohydride or sodium cyanoborohydride in a solvent such as dichloroethane, methanol or dimethylformamide. The product II can be deprotected to give the final compounds III with trifluoroacetic acid in methylene chloride. The final product III is isolated in the salt form, for example, as a trifluoroacetate, hydrochloride or acetate salt, among others. The product diamine III can further be selectively protected to obtain IV, which can subsequently be reductively alkylated with a second aldehyde to obtain V. Removal of the protecting group, and conversion to cyclized products such as the dihydroimidazole VII can be accomplished by literature procedures.
Alternatively, the aminomethylbenzamide subunit can be reductively alkylated with other aldehydes such as 1-trityl-4carboxaldehyde or 1-trityl-4-imidazolylacetaldehyde, to give products such as VIII (Reaction Scheme The trityl protecting group can be removed from VIII to give IX, or alternatively, VIII can first be treated with an alkyl halide then subsequently deprotected to give the alkylated imidazole X. Alternatively, the aminomethylbenzamide subunit can be acylated or sulfonylated by standard techniques.
1 WO 96/30015 PCT/US96/03980 -46- The imidazole acetic acid XI can be converted to the acetate XIII by standard procedures, and XIII can be first reacted with an alkyl halide, then treated with refluxing methanol to provide the regiospecifically alkylated imidazole acetic acid ester XIV. Hydrolysis and reaction with the aminomethylbenzamide subunit in the presence of condensing reagents such as l-(3-dimethylaminopropyl)-3ethylcarbodiimide (EDC) leads to acylated products such as XV.
If the aminomethylbenzamide subunit is reductively alkylated with an aldehyde which also has a protected hydroxyl group, such as XVI in Reaction Scheme H, the protecting groups can be subsequently removed to unmask the hydroxyl group (Reaction Schemes H, The alcohol can be oxidized under standard conditions to e.g. an aldehyde, which can then be reacted with a variety of organometallic reagents such as Grignard reagents, to obtain secondary alcohols such as XX. In addition, the fully deprotected amino alcohol XXI can be reductively alkylated (under conditions described previously) with a variety of aldehydes to obtain secondary amines, such as XXII (Reaction Scheme or tertiary amines.
The Boc protected amino alcohol XVIII can also be utilized to synthesize 2-aziridinylmethylpiperazines such as XXIII (Reaction Scheme Treating XVIII with 1,l'-sulfonyldiimidazole and sodium hydride in a solvent such as dimethylformamide led to the formation of aziridine XXIII The aziridine reacted in the presence of a nucleophile, such as a thiol, in the presence of base to yield the ring-opened product
XXIV.
In addition, the aminomethylbenzamide subunit can be reacted with aldehydes derived from amino acids such as O-alkylated tyrosines, according to standard procedures, to obtain compounds such as XXX, as shown in Reaction Scheme L. When R' is an aryl group, XXX can first be hydrogenated to unmask the phenol, and the amine group deprotected with acid to produce XXXI. Alternatively, the amine protecting group in XXX can be removed, and O-alkylated phenolic amines such as XXXII produced.
WO 96/30015 PCTfUS96/03980 -47- Reaction Scheme M illustrates a one pot synthesis of an instant compound wherein the N-terminus nitrogen is substituted with two different non-sulfhydryl-containing moieties. Thus, the aminomethylbenzamide subunit is treated with one equivalent of an appropriate aldehydea and, after the reductive adduct has been formed, the in situ intermediate is treated with an equivalent of a different aldehyde.
Similar procedures as are illustrated in Reaction Schemes E- M may be employed using other intermediates such as those whose synthesis is illustrated in Reaction Schemes B D.
WO 96/30015 PCT/US96103980 -48- SCHEME E
H
2
N
Boc Boo NHI
I
OR 6 Boo NH CHO NaBH(OAc) 3 Et 3 N CICH 2
CH
2
CI
o a 6 FC2 )-KN
OR
6
C
3 H H C1 2
NH
2 N
H
NH
2 R a -OR 6
BOC
2 0
CH
2
CI
2 BocNH
N
H
NH
2
IV
CHO
NaBH(OAC) 3 Et 3 N CICH 2
CH
2
CI
R
2 a'
R
2 WO W630015 PCTIUS96/03980 -49- SCHEME E (continued)
NH
NH
2 N'
NH
OR
6
CF
3
CO
2 H, CH 2
C
2 y NaHCO 3 0 <0R 6
NC
0 AgON A~ R 2 b FrN'
R
2 b WO 96/30015 WO 9630015PCTfUS96/03980 SCHEME F
H
2 N j NaBH
(OAC)
3 Et 3 N CICH 2
CH
2
CI
(CH
2 )nCHO
N
Tr Ar
K(CH
2 )nCHO
N
N
NaBH (OAc) 3 Et 3 N CICH 2
CH
2
CI
R
2 a'
CF
3 C0 2 H, CH 2
CI
2 (0 2
H
5 3 SiH
(CH
2 )n+l N H
N
H
,t OR 6
NN
N- Hi N x R 2 a R 2 b OR3a H 0 I WO 96/30015 PTU9/38 PCT/US96/03980 -51- SCHEME G
NCH
2
CO
2
H
N
H
CH
3 0H-
HCI
-HCI
N-CH
2 00 2
CH
3 1) ArCH 2 X CH 3
CN
(C
6
H
5 3 CBr 3 k\ reflux
(C
2
H
5 3 N N 2)C 3 0H, reflux DMF Tr TrI Ar' N-CH 2
CO
2
CH
3
N
XIV
Ar'\ N CH 2 00 2
H
N
2.5N HCI aq 5500 I WO096/30015 PCT/US96/03980 52- SCHEME H N CH 2
CO
2
H
N
H
2
N~
EDC -HCI HOBt
R
2 b Ar, R 2 b WO 96/30015 PCTIUS96/03980 53 SCHEME I 0 R3
H
2 N N ,,OR 6 H 0 R 2 a
R
2 b NaBH(OAC) 3 BnOI BocNH CHO xvi BnO
N
H
NHBoc 09 3 20% Pd(OH) 2
H
2
CH
3 0H
CH
3
CO
2
H
xvi"
HO
H
NHBoc
CICOCOC'
DMSO
CH
2
CI
2
(C
2
H
5 3
N
xv"'l WO 96130015 PCT/US96/03980 -54- SCHEME I (CONTINUED) R'MgX
(C
2
H
5 2 0
XIX
R
2 a' 'jR2b I WO 96/30015 WO 9630015PCTIUS96/03980 55 SCHEME J HO
N
Hf
R
2 a R
XVIII
HO N Hi
NH
2 2 2
R
2 Rb a
CF
3
CO
2
H
'r R 6CH 2
CI
2 0
R'CHO
-OR 6 NaBH(OAc) 3
CICH
2
CH
2
CI
XXI
-OR 6
NH
R'CH
2 R 2 b
XXII
WO 96/30015 WO 9630015PCTfUS96/03980 56- SCHEME K H H NK NN NaH, DMF 000
R'SH
(0 2
H
5 3
NA
CH
3 0H xviI,
N
H
0 a N'
OR
6
H
R
2 a 2 b
XXII'
NH
2 R 2 b
XXIV
WO 96/30015 WO 9630015PCT/US96103980 57 SCHEME L
HO-
1) Boc 2 O, K 2 00 3
THF-H
2 0 2) 0H 2
N
2 EtOAc oN H 2 N- 'C0 2
H
xxv LiAIH 4
THE
0-20 0
C
xxv'
R'CH
2
X
CS
2
CO
3
DMF
CH
2
OH
xxv"l
R'CI
p R'C H 2 0 yridie
C
DMSO
(0H 5 3 N BocN H CHO F -CH 2
OH
xxv"'l 200C xxix WO 96/30015 WO 9630015PCT/US96O3980 58 SCHEME L (continued) BocNH_ CHO
XXIX
NaBH(OAC) 3
CICH
2
CH
2
CI
-OR 6 1) 20% Pd(OH) 2
CH
3 OH, CH 3 00 2
H
2) HCt, EtOAc
XXX
ETOAc RaNH 2 R2
OR
6 Xxxii 0 R 2 b I WO 96/30015 W096/0015PCT/US96/03980 59 SCHEME M o
R
3 a
H
2 N N JC0 2 R 6 I H 1) ROHO, NaBH(OAC) 3
CICH
2
CH
2
CI
2) R'CHO, NaBH(OAC) 3
CICH
2
CH
2
CI
NaCH
H
2 0, CH 3
OH;
R3a 'ill C02R6 R" 11 1 I o R 3 a NI N N JAC2 Rl H C 2 WO 96/30015 PCT/US96/03980 The -NR 4
R
5 moiety of the compounds of the instant invention may provide advantages over a cysteinyl moiety that is incorporated in other types of molecules that are known to be inhibitors of farnesyl protein transferase. In particular, modification of the benzodiazepine compounds described in published PCT application
WO
94/26723 with the such -NR 4
R
5 substituents as described herein will provide inhibitors of farnesyl protein transferase of the following formulae A and B: Ra
N
Rb R7benz wherein the substituents R, R' and R 2 5 are as defined in WO 94/26723, R4benz, R4'benz, R7benz and Wbenz are R 4
R
4
R
7 and W respectively as defined in WO 94/26723 and Ra and Rb are defined as R 4 and R 5 are defined herein respectively.
WO 96/30015 PCTUS96O398O -61- Preferably,the following combinations of Ra and Rb are selected for incorporation into the compounds of formulae A and B: Rb imidazol-4-ylacetyl
H
imidazol-4-ylmethyl imidazol-4-ylmethyl 4-nitrobenzyl imidazol-4-ylmethyl 3-(4-cyanobenzyl)-imidazol-4-
H
-acetyl__ 3-(4-cyanobenzyl)-imidazol-4- CH3 acetyl Most preferably, the benzodiazepine compound would be selected from the following formulae: W Ibenz n I\R b wherein R and R' are as defined in WO 94/26723 and W'benz is W'as defined in WO 94/26723 and Ra' and Rb are defined as R 4 and R 5 are defined herein respectively.
Such benzodiazepine analogs may be synthesized by techniques well known in the art, as well as procedures outlined in WO 94/26723. General methods of synthesis of the benzediazapine analogs of this invention are shown in Schemes N, P and Q. Typically a convergent route is employed, which joins the key intermediate 9 WO 96/30015 PCTIUS96/03980 62- (Scheme N) with suitably functionalized amine and Ra and Rb components (Schemes P and Q) using standard amide bond-forming procedures.
As shown in Scheme N, the protected amino acid 9 may be prepared from a suitably substituted 2 -aminobenzophenone Many 2aminobenzophenones are known in the art or are available form commercial sources such as Aldrich Chemical Co. General methods for the synthesis of new 2-aminobenzophenones may be found in the literature Walsh, D. A. Synthesis, 677-688 (1980).
Acylation of 1 with a haloacetyl halide, such as bromoacetyl bromide in a suitable solvent mixture, such as water/ CH2C12, typically at temperatures ranging from 0° C to 24° C, produces amide 2. Reaction of 2 with ammonia in a polar solvent such as methanol at 25 to 75 °C then gives the 1,4-benzodiazepin-2-one 3, after evaporation of the solvent.
Alkylation of 3 with a substituted organic ester preferably tert-butyl bromacetate, in the presence of a base, preferably Cs2CO3 in 1-methyl-2pyrrolidinone at ambient temperature, gives 5. Alternatively, 3 may be alkylated at N-l with a variety of other alkylating agents, for instance, esters of substituted or unsubstituted acrylates, 4-bromobutanoates, etc.
Branched compounds R4benz and/or R4'benz may be prepared by generation of the polyanion of 5 with base and alkylation with an appropriate alkyl halide. Subsequent to alkylation, the ester of 5 may be cleaved with an acid such as TFA (for the tert-butyl esters) or under mild aqueous base hydrolysis (for other alkyl esters) at temperatures between 0 and 25 °C.
The acid 6 is converted to amino acid 8 via reaction of the dianion, generated with at least two equivalents of a strong base with an electrophilic aminating agent. Alternatively, 6 may be halogenated and reacted with an amine source such as azide (followed by reduction) or ammonia. Preferably, 6 is reacted with 4 equivalents of potassium tertbutoxide in glyme at -5 °C for 30 min and treated with 1.1 equivalents of isobutyl nitrite. The resulting oxime 7 can then be reduced to the racemic amino acid 8 using a variety of reductants, preferably hydrogenation at WO 96/30015 PCT/US96/03980 63psig in the presence of Ruthenium on carbon or Raney nickel in methanol at 50 to 70 "C for 1-4 days.
Amino acid 8 is then suitably protected for selective coupling at the carboxyl terminus. For example, 8 can be converted to the N-BOC derivative 9 using standard amino acid protection conditions, preferably, reaction with equimolar amounts of di-tert-butyl dicarbonate and triethyl amine in DMF/ water at ambient temperature.
For compounds where Ra 9 can be alkylated at nitrogen with a wide variety of alkylating agents including n-alkyl, branched alkyl, and benzyl, according to the standard procedure of Benoiton, et al., Can.
J. Chem. 1977, 55, 906. For example, reaction of 9 with at least 2 equivalents of base and an alkylating agent in a polar, aprotic solvent at 0 to 50 "C for 0.5 to 48 h give 10. Also, the reactions shown in Schemes E M may be utilized with the compound 9.
WO 96/30015 PCTIUS96/03980 -64- Brlj Br H 0 C 0
NH
3 0
TEA
HO
0
HO
KOt-Bu
ONO
H
2 /Ru WO 96/30015 PCTIUS96/03980 65 SCHEME N(continued)
HO
0
(BOC)
2 0
NH
2
BOC
HO
0 RaXL base Schemes P Compounds 9 and 10 can be further elaborated according to Schemes P. In general, the carboxylic acid function of 9 and 10 is reacted with a suitably protected amine component using standard solid phase (Scheme P) or solution phase peptide synthesis procedures. The BOC or other protecting group of N-3 of the benzodiazepinone is removed and the amine function then coupled with a third component, for example, a suitably protected amino acid, and then deprotected, again employing standard procedures. The resulting product is subsequently purified by chromatography or crystallization.
WO 96130015 PCT/US96/03980 66 SCHEME P protected protected
HO
0 .1011-1
BOO
protected deprotect ~RI RbXL WO 96/30015 PCT/US96/03980 -67- SCHEME P (continued) deprotect, cleave from resin
N
Rb Alternatively, 3 may be directly alkylated with the "top" sidechain in one intact piece, as shown in Scheme Q. Reaction of 3 with an alkyl halide such as a suitably substituted benzyl bromide, alkyl bromide, in the presence of a base, preferably NaH or Cs2CO3, gives 11, which may be processed according to the reactions illustrated in Scheme I to provide the desired FPTase inhibitors.
WO 96/30015 WO 9630015PCTIUS96/03980 68 SCHEME Q R 4benz 4bn halo Wbenz-P.G.
,Wbenz~p.G.
0 j KOt-Bu -NONO-r -N2(BOC) 2 0 R 4'benz R4'benz
R
4 benz .WbenzP.G.
H
2 /Ru ,Wbenz-P.G.
H
BOC
wherein P.G. is a suitably selected protecting group which is utilized if necessary.
WO 96/30015 PCT/US96/03980 -69- The compounds of this invention inhibit Ras farnesyl transferase which catalyzes the first step in the post-translational processing of Ras and the biosynthesis of functional Ras protein. These compounds are useful as pharmaceutical agents for mammals, especially for humans. These compounds may be administered to patients for use in the treatment of cancer. Examples of the type of cancer which may be treated with the compounds of this invention include, but are not limited to, colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias.
The compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
For oral use of a chemotherapeutic compound according to this invention, the selected compound may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added. For intramuscular, intraperitoneal, subcutaneous and intravenous use, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled in order to render the preparation isotonic.
The present invention also encompasses a pharmaceutical composition useful in the treatment of cancer, comprising the WO 96/30015 PCT/US96/03980 administration of a therapeutically effective amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents. Suitable compositions of this invention include aqueous solutions comprising compounds of this invention and pharmacologically acceptable carriers, saline, at a pH level, 7.4. The solutions may be introduced into a patient's intramuscular blood-stream by local bolus injection.
When a compound according to this invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
In one exemplary application, a suitable amount of compound is administered to a mammal undergoing treatment for cancer.
Administration occurs in an amount between about 0.1 mg/kg of body weight to about 20 mg/kg of body weight per day, preferably of between mg/kg of body weight to about 10 mg/kg of body weight per day.
The compounds of the instant invention are also useful as a component in an assay to rapidly determine the presence and quantity of farnesyl-protein transferase (FPTase) in a composition.
Thus the composition to be tested may be divided and the two portions contacted with mixtures which comprise a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and famesyl pyrophosphate and, in one of the mixtures, a compound of the instant invention. After the assay mixtures are incubated for an sufficient period of time, well known in the art, to allow the FPTase to farnesylate the substrate, the chemical content of the assay mixtures may be determined by well known immunological, radiochemical or chromatographic techniques. Because the compounds of the instant invention are selective inhibitors of FPTase, absence or quantitative reduction of the amount of substrate in the assay mixture without the compound of the instant invention relative to the presence of the unchanged substrate in the assay containing the WO 96130015 PCT/US96/o398o -71 instant compound is indicative of the presence of FPTase in the composition to be tested.
It would be readily apparent to one of ordinary skill in the art that such an assay as described above would be useful in identifying tissue samples which contain farnesyl-protein transferase and quantitating the enzyme. Thus, potent inhibitor compounds of the instant invention may be used in an active site titration assay to determine the quantity of enzyme in the sample. A series of samples composed of aliquots of a tissue extract containing an unknown amount of farnesyl-protein transferase, an excess amount of a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and famrnesyl pyrophosphate are incubated for an appropriate period of time in the presence of varying concentrations of a compound of the instant invention. The concentration of a sufficiently potent inhibitor one that has a Ki substantially smaller than the concentration of enzyme in the assay vessel) required to inhibit the enzymatic activity of the sample by is approximately equal to half of the concentration of the enzyme in that particular sample.
EXAMPLES
Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the invention and not limitative of the reasonable scope thereof.
The standard workup referred to in the examples refers to solvent extraction and washing the organic solution with 10% citric acid, sodium bicarbonate and brine as appropriate. Solutions were dried over sodium sulfate and evaporated in vacuo on a rotary evaporator.
WO 96/30015 PCT/US96/03980 -72- EXAMPLE 1 1 (S)-carboxy-3-methylthiopropyl)-3-(4-imidazolylmethyl)aminomethvlbenzamide dihydrochloride Step A: Preparation of N-(1(S)-carbomethoxy-3-methylthiopropyl)- 3-chloromethylbenzamide To a solution of methionine methyl ester hydrochloride (10.56 g, 52.9 mmol) and 4-N-methylmorpholine (21.34 g, 211.6 mmol) under nitrogen in 200 mL of methylene chloride at OC was added 3chloro-methyl benzoyl chloride (10.00 g, 52.9 mmol) dropwise via syringe. After addition the cooling bath was removed and the resulting solution was stirred for 16 h at 20 0 C. The methylene chloride solution was extracted with 125 mL each of water, 2% potassium hydrogen sulfate, saturated sodium hydrogen carbonate, and saturated sodium chloride. The methylene chloride was dried over magnesium sulfate and concentrated in vacuo to the title compound as an oil. 1 HNMR (300 MHz, CDC13) 8 7.85 (1H, 7.76 (1H, d, J=8 Hz), 7.56 (1H, d, J=8 Hz), 7.45 (1H, t, J=8 Hz), 6.96 (1H, d, J=7 Hz), 4.94 (1H, q, J=5 Hz), 4.62 (2H, 3.81 (3H, 2.60 (2H, t, J= 8Hz), 2.30 (1H, 2.15 (1H, m), 2.12 (3H, s).
Step B: Preparation of N-(1 (S)-carbomethoxy-3-methylthiopropyl)- 3-azidomethylbenzamide To a stirred solution of the product from Step A (13.52 g, 42.80 mmol) in 50 mL of dimethylsulfoxide under nitrogen was added lithium azide (2.3 g, 47.10 mmol). The solution was stirred for 2 h The reaction mixture was then partitioned with 300 mL of ethyl acetate and 200 mL of water. The ethyl acetate layer was washed with 125 mL of saturated sodium chloride, dried over magnesium sulfate and concentrated in vacuo to afford the title compound as an oil. 1
HNMR
(300 MHz, CDC13) 5 7.75 (2H, 7.47 (2H, 7.02 (1H, d, J=8 Hz), 4.94 (1H, q, J=5 Hz), 4.41 (2H, 3.80 (3H, 2.60 (2H, t, J=6 Hz), 2.30 (1H, 2.15 2.11 (3H, s).
WO 96/30015 PCT/US96/03980 -73- Step C: Preparation of N-(1(S)-carbomethoxy-3-methylthiopropyl)- 3-aminomethylbenzamide To a solution of the product from Step B (11.8 g, 35.08 mmol) in 150 mL of methanol under nitrogen was added 1.5 g palladium on carbon. Hydrogen was applied to the mixture at 1 atmosphere for 1.5 h. The reaction mixture was filtered and concentrated in vacuo to obtain 10.3 g (34.76 mmol) of crude product as an oil. The crude product was chromatographed on 500 g of silica gel with chloroform/methanol 95/5 as eluant to afford the title compound as an oil.
1 HNMR (300 MHz, CDC13) 8 7.78 (1H, 7.68 (1H, d, J=7 Hz), 7.47 (1H, d, J=7 Hz), 7.40 (1H, t, J=8 Hz), 7.02 (1H, d, J=7 Hz), 4.93 (1H, q, Hz), 3.92 (2H, 3.79 (3H, 2.59 (2H, t, J=8 Hz), 2.24 (1H, m), 2.12 (1H, 2.10 (3H, 1.85 (2H,s).
Step D: Preparation of N-(1 (S)-carbomethoxy-3-methylthiopropyl) 3- [(1-triphenylmethyl)-4-imidazolylmethyl]aminomethyl benzamide To a solution of the product from Step C (0.228 g, 0.767 mmol) in 10 mL of 1,2-dichloroethane was added glacial acetic acid dropwise until a pH 5.5 was achieved. To this mixture at 20 0 C. was added 0.5 g of crushed 4A molecular sieves, sodium triacetoxyborohydride (0.487 g, 2.30 mmol), and 1-(triphenylmethyl)-4imidazole carboxaldehyde (0.130 g, 0.384 mmol). The resulting solution was stirred for 12-72 h. The reaction mixture was filtered through celite and partitioned with 125 mL of water and 150 mL of ethyl acetate. The ethyl acetate layer was washed with 125 mL each of saturated sodium hydrogen carbonate and saturated sodium chloride, dried over magnesium sulfate, and concentrated in vacuo to yield 0.363 g of crude product. The crude product was chromatographed on silica gel eluting with chloroform/methanol 95/5 to afford the title compound. 1
HNMR
(300 MHz, CDC13) 8 7.83 (1H, 7.71 (1H, d, J=7 Hz), 7.40 (4H, m), 7.32 (8H, 7.25 (1H, 7.12 (7H, 6.71 (1H, 4.93 (1H, q, WO 96/30015 PCT/US96/03980 -74- Hz), 3.85 (2H, 3.77 (3H, 3.71 (2H, 2.58 (2H, t, J=8 Hz), 2.25 (1H, 2.10 (1H, 2.09 (3H, s).
Step E: Preparation of N-(1 (S)-carbomethoxy-3-methylthiopropyl)- 3-(4-imidazolylmethyl)aminomethylbenzamide dihydrochloride To a solution of the product from Step D (0.220 g, 0.356 mmol) in 10 mL of methylene chloride was added triethylsilane (0.165 g, 1.42 mmol) and 5 mL of trifluoroacetic acid. The solution was stirred for 45 min, evaporated in vacuo, and partitioned with hexane and 0.1% trifluoroacetic acid in water:methanol 2:1. The 0.1% trifluoroacetic acid/water-methanol solution was injected directly onto a Delta-Pak (C- 18, 100A, 15 mm, 40mm x 100mm) prep HPLC column. The gradient at mL/min. was 100% 0.1% TFA/water for 5 min. followed by 0.1% TFA/water 0.1% TFA/acetonitrile to 70% 0.1% TFA/water 0.1% TFA/acetonitrile over a period of 40 min. The pure fractions were pooled, evaporated in vacuo to near dryness, and then taken up in mL of water. This water solution was passed through a 1.2 gm. column of Bio-Rad AG 3-X4 chloride anion exchange resin. The resulting aqueous column eluant was lyophillized overnight to yield the title compound as a solid. 1 HNMR (300 MHz, CD30D) 8 9.04 (1H, 8.06 (1H, 7.96 (1H, d, J=8 Hz), 7.83 (1H, 7.76 (1H, d, J=8 Hz), 7.63 (1H, t, J=8 Hz), 4.81 (1H, q, J=5 Hz), 4.52 (2H, 4.42 (2H, 3.77 (3H, 2.63 (2H, 2.22 (1H, 2.16 (1H, 2.13 (3H, FAB mass spectrum m/e 377 Analysis calculated for C18H24N403S 3.3 HC1: C, 43.57; H, 5.55; N, 11.29. Found: C, 43.56; H, 5.54; N, 11.82.
Step F: Preparation of N-(1(S)-carboxy-3-methylthiopropyl)-3-(4imidazolylmethyl)aminomethvl benzamide dihydrochloride The product from Step E (0.030 g, 0.067mmol) was dissolved in 5 mL of methanol and 3 mL of 5% sodium hydroxide and stirred for 1 h under nitrogen. The reaction mixture was injected directly onto a preparative reverse phase HPLC column with conditions identical WO 96/30015 PCT/US96/03980 as in the preparation of the compound in Step E. Pure fractions were pooled, evaporated in vacuo, and the sample was converted to the hydrochloride salt as before. Lyophillization overnight afforded 0.022 g (0.051 mmol) of the title compound as a solid. 1 HNMR (300 MHz, CD30D) 8 9.06 (1H, 8.06 (1H, 7.96 (1H, d, J=8 Hz), 7.83 (1H, s), 7.76 (1H, d, J=8 Hz), 7.61 (1H, t, J=8 Hz), 4.78 (1H, q, J=5 Hz), 4.53 (2H, 4.47 (2H, 2.63 (2H, 2.25 (1H, 2.15 (1H, 2.13 (3H, FAB mass spectrum m/e 363 Analysis calculated for C17H22N403S 3.3 HC1 0.5 H20: C,41.57; H, 5.40; N, 11.41. Found: C, 41.54; H, 5.42; N, 11.05.
EXAMPLE 2 N-(1(S)-carboxy-3-methylthiopropyl)-3-[N,N-bis(4-imidazole methyl)aminomethyllbenzamide dihydrochloride Step A: Preparation of N-(1(S)-carbomethoxy-3-methylthiopropyl)- 3-[N,N-bis[(1-triphenylmethyl)-4-imidazolylmethyl]aminomethvl-benzamide To a solution of the product from Example 1, Step C (0.100 g, 0.357 mmol) in 10 mL of 1,2-dichloroethane was added glacial acetic acid dropwise until the pH was 5.5. To this mixture at 20 0 C was added g of crushed 4A sieves, sodium triacetoxyborohydride (0.226 g, 2.30 mmol), and 1-(triphenylmethyl)-4-imidazole carboxaldehyde (0.130 g, 1.07 mmol). The resulting solution was stirred for 12-72 h. The reaction mixture was filtered through celite and partitioned with 125 mL of water and 150 mL of ethyl acetate. The ethyl acetate layer was washed with 125 mL each of saturated sodium hydrogen carbonate and saturated sodium chloride, dried over magnesium sulfate, and concentrated in vacuo to yield the title compound.
Step B: Preparation of N-(1 (S)-carbomethoxy-3-methylthiopropyl)- 3-[N,N-bis( 4 -imidazolylmethyl)aminomethyl]benzamide dihydrochloride WO 96/30015 PCT/US96/03980 -76- To a solution of the product from Step A (0.320 g, 0.341 mmol) in 10 mL of methylene chloride was added triethylsilane (0.159 g, 1.36 mmol) and 5 mL of trifluoroacetic acid. The solution was stirred for min, evaporated, and partitioned between hexane and 0.1% TFA in water-methanol 2:1. The 0.1% TFA/water:methanol solution was injected directly onto a Delta-Pak (C-18, 100A, 15 mm, 40mm x 100mm) preparative HPLC column. The gradient at 40 mL/min was 100% 0.1% TFA/water for 5 min followed by 95% 0.1% TFA/water to 60% 0.1% TFA/water :40% 0.1% TFA/acetonitrile over 40 min. The pure fractions were pooled, evaporated to near dryness, and then taken up in 5 mL of water. The aqueous solution was passed through a 1.2 gm. column of Bio-Rad AG 3-X4 chloride anion exchange resin. The resulting aqueous column eluant was lyophillized overnight to yield the title compound as a solid. 1 HNMR (300 MHz, CD30D) 8 8.92 (2H, 7.94 (1H, 7.78 (1H, d, J=8 Hz), 7.62 (2H, 7.58 (1H, d, J=8 Hz), 7.44 (1H, t, J=8 Hz), 4.81 (1H, q, J=5 Hz), 4.06 (4H, 3.93 (2H, 3.77 (3H, 2.63 (2H, 2.22 (1H, 2.16 (1H, 2.13 (3H, FAB mass spectrum m/e 457 Analysis calculated for C22H28N603S 4.8 HC1 0.2 C, 41.66; H, 5.28; N, 13.25. Found: C, 41.62; H, 5.27; N, 13.02 Step C: Preparation of N-(1(S)-carboxy-3-methylthiopropyl)-3- [N,N-bis( 4 -imidazolemethyl)aminomethyl]benzamide dihvdrochloride The compound from Step B (0.035 g, 0.052 mmol) was dissolved in 5 mL of methanol and 3 mL of 5% sodium hydroxide and stirred for 1 hr under nitrogen. The reaction mixture was injected directly onto a preparative HPLC column with conditions identical as in Step B.
Pure fractions were pooled, evaporated, and the sample converted to the hydrochloride salt as before. Lyophilization overnight afforded the title compound as a solid. 1 HNMR (300 MHz, CD30D) 8 8.88 (2H, s), 7.87 (1H, 7.75 (1H, d, J=8 Hz), 7.55 (1H, 7.50 (1H, d, J=8 Hz), 7.42 (1H, t, J=8 Hz), 4.78 (1H, q, J=5 Hz), 3.88 (4H, 3.77 (2H, 2.63 (2H, 2.25 (1H, 2.15 (1H, 2.13 (3H, FAB mass spectrum WO 96/30015 PCT/US96/03980 -77m/e 443 Analysis calculated for C21H26N603S 5.4 HC1 C, 37.91; H, 5.21; N, 12.63. Found: C, 37.97; H, 5.22; N, 12.37.
EXAMPLE 3 N-(l(S)-carboxy-3-methylthiopropyl) 4 -imidazolylmethyl)
-N-
methvlaminomethyllbenzamide dihydrochloride Step A: Preparation of Methyl 3-chloromethyl benzoate To a solution of triethylamine (11.0 mL) in methanol (150 mL) at OC was added 3 -chloromethylbenzoyl chloride (5.0 g) dropwise.
After stirring at 200 C for 0.5 h the solution was concentrated in vacuo.
The residue was partitioned with 125 mL of water and 150 mL of ethyl acetate. The ethyl acetate layer was washed with 125 mL each of saturated sodium hydrogen carbonate, 2% potassium hydrogen sulfate and saturated sodium chloride, dried over magnesium sulfate, and concentrated in vacuo to yield the title compound. 1 HNMR (300 MHz, CDC13 8 8.07 (1H, 7.99 (1H, d, J=8 Hz), 7.59 (1H, d, J=8 Hz), 7.43 (1H, t, J=8 Hz), 4.62 (2H, 3.92 (3H, s).
Step B: Preparation of Methyl 3 -azidomethylbenzoate Starting with the product from Step A the method used in Step B of Example 1 was used to prepare the title compound.
Step C: Preparation of Methyl 3-aminomethyl benzoate Starting with the product from Step B the method used in Step C of Example 1 was used to prepare the title compound.
Step D: Preparation of Methyl 3 -(t-butyloxycarbonyl)aminomethyl benzoate To a solution of the product from Step C (1.14 g) in methylene chloride (50 mL) was added triethylamine (2.90 mL) and di- WO 96/30015 PCT/US96/03980 -78tert-butyl dicarbonate (1.67 g) and the mixture was stirred 16 h. The solution was partitioned with water and methylene chloride. The methylene chloride layer was washed with saturated sodium hydrogen carbonate, 2% potassium hydrogen sulfate and saturated sodium chloride, dried over magnesium sulfate, and concentrated in vacuo to yield 1.71 g of the crude product. Chromotography on silica gel with hexane/ethyl acetate 9/1 yielded the title compound. 1 HNMR (300 MHz, CDC13 7.95 (1H, 7.93 (1H, d, J=8 Hz), 7.49 (1H, d, J=8 Hz), 7.41 (1H, t, J= 8 Hz), 4.90 (1H, 4.37 (2H, d, J=6 Hz), 3.92 (3H, 1.45 (9H, s).
Step E: Preparation of Methyl 3- [(t-butyloxycarbonyl)-N-methylaminomethyll benzoate To a solution of the product from Step E (1.42 g) in dimethylformamide (30 mL) at 00 C was added sodium hydride (0.43 g, 60% dispersion in minerol oil). After stirring for 0.5 h methyl iodide (0.40 mL) was added and the mixture was stirred 16 h at 200 C. The solution was concentrated in vacuo and the residue was partitioned between ethyl acetate and water. The ethyl acetate layer was washed with saturated sodium hydrogen carbonate, 2% potassium hydrogen sulfate and saturated sodium chloride, dried over magnesium sulfate, and concentrated in vacuo to yield the crude product. Chromotography on silica gel with hexane/ethyl acetate 9/1 yielded 0.35 g of the title compound. 1 HNMR (300 MHz, CDC13 8 7.93 (2H, 7.42 (2H, m), 4.45 (2H, 3.92 (3H, 2.83 (3H, 1.47 (9H, s).
Step F: Preparation of 3- [(t-butyloxycarbonyl)-N-methylaminomethyll benzoic acid To a solution of the product from Step E (0.35 g) in methanol was added 5% sodium hydroxide. After stirring for 2 h the methanol was evaporated and the aqueous layer was adjusted to pH 3 with 2% potassium hydrogen sulfate. The aqueous layer was extracted with ethyl acetate several times. The ethyl acetate layer was washed with saturated sodium chloride, dried over magnesium sulfate, and concentrated in vacuo to yield the title compound.
WO 96/30015 PCT/US96/03980 -79- Step G: Preparation of N-(1 (S)-carbomethoxy-3-methylthiopropyl)- 3-r(t-butvloxycarbonvyl-N-methylaminomethylbenzamid.
To a solution of the product from Step F (0.27 g) in dimethylformamide (10 mL) was added hydroxybenzotriazole (0.16 g), EDC (0.19 N-methylmorpholine (0.40 mL), and methione methyl ester hydrochloride (0.203 mg). After stirring for 2 h the solution was concentrated in vacuo and the residue was partitioned with water and ethyl acetate. The ethyl acetate layer was washed with saturated sodium hydrogen carbonate, 2% potassium hydrogen sulfate and saturated sodium chloride, dried over magnesium sulfate, and concentrated in vacuo to yield the title compound. 1 HNMR (300 MHz, CDC13 8 7.70 (2H, 7.40 (2H, 6.95 (1H, d, J=7 Hz), 4.94 (1H, q, J=7 Hz), 4.45 (2H, 3.81 (3H, 2.82 (3H, 2.59 (2H, 2.30 (1H, 2.13 (1H, 2.12 (3H, 1.46 (9H, s).
Step H: Preparation of N-(1 (S)-carbomethoxy-3-methylthiopropyl)- 3-(N-methvlaminomethvl)benzamide trifluoroacetate To a solution of the product from Step G in methylene chloride was added trifluoroacetic acid (33% by volume). After stirring for 1 h the solution was concentrated in vacuo to yield the title compound.
Step I: Preparation of N-(l(S)-carbomethoxy-3-methylthiopropyl)- 3-[(1-triphenylmethyl)-4-imidazolylmethyl-N-methylaminomethyllbenzamide Starting with the product from Step H (0.18 g) the method described in Step D of Example 1 was used to prepare the title compound.
Step J: Preparation of N-(1 (S)-carbomethoxy-3-methylthiopropyl)- 3-[(4-imidazolylmethyl) -N-methyl-minomethyl]benzamide dihydrochloride WO 96/30015 PCT/US96/03980 Starting with the compound from Step I (0.24 g) the method described in Step E of Example 1 was used to prepare the title compound.
FAB mas spectrum m/e 391 Analysis for C19H26N403S 5.0 HCI 0.5 Calculated: C, 39.32; H, 5.56; N, 9.65; Found: C, 39.33; H, 5.57; N, 9.38.
Step K: Preparation of N-(1 (S)-carboxy-3-methylthiopropyl)-3-[(4imidazolemethyl) -N-methyl-aminomethyl]benzamide dihvdrochloride Starting with the compound from Step J (0.035 g) the method described in Step F of Example 1 was used to prepare the above title compound. FAB mas spectrum m/e 377 Analysis for C18H24N403S 3.70 HCI 0.2 Calculated C, 42.05; H, 5.51; N, 10.90; Found: C, 42.09; H, 5.49; N, 10.70.
EXAMPLE 4 N-(1(S)-carboxy-3-methylthiopropyl) 4-[(4-imidazolylmethyl)aminolbenzamide dihydrochloride Step A: Preparation of 4-t-butvloxycarbonyl- aminobenzoic acid Starting with 4-aminobenzoic acid (2.00 g) dissolved in tetrahydrofuran (50 mL) and 5% sodium hydroxide (15 mL) the method described in Step D of Example 3 was used to prepare the title compound. After extractive work up obtained the title compound.
1 HNMR (300 MHz, CDC13 8 8.04 (2H, d, J=9 Hz), 7.46 (2H, d, J=9 Hz), 6.75 (1H, 1.46 (9H, s).
Step B: Preparation of N-(1(S)-carbomethoxy-3-methylthiopropyl)- 4 -(t-butvloxycarbonl)aminobenzamide To a solution of the product from Step A (0.5 g) in dimethylformamide (20 mL) was added hydroxybenzotriazole (0.37 g), WO 96/30015 PCT/US96/03980 -81- EDC (0.51 N-methylmorpholine 0.8 mL), and methione methyl ester hydrochloride (0.49 After stirring for 16 h the solution was concentrated in vacuo and the residue was partitioned with water and ethyl acetate. The ethyl acetate layer was washed with saturated sodium hydrogen carbonate, 2% potassium hydrogen sulfate and saturated sodium chloride, dried over magnesium sulfate, and concentrated in vacuo to yield the title compound.
Step C: Preparation of N-(1 (S)-carbomethoxy-3-methylthiopropyl)- 4-aminobenzamide To a solution of the product from Step B in methylene chloride was added trifluoroacetic acid (33% by volume). After stirring for 1 h the solution was concentrated in vacuo to yield the trifluoroacetate salt of the product (0.59 This product was partioned between ethyl acetate and saturated sodium bicarbonate. The ethyl acetate layer was washed with saturated sodium chloride, dried over magnesium sulfate, and concentrated in vacuo to yield the title compound. 1 HNMR (300 MHz, CDC13 8 7.64 (2H, d, J=8 Hz), 6.75 (1H, d, J=8 Hz), 6.65 (2H, d, J=8 Hz), 4.90 (1H, q, J=5 Hz), 3.78 (3H, 2.57 (2H, 2.27 (1H, m), 2.08 (4H, m).
Step D: Preparation of N-(1 (S)-carbomethoxy-3-methylthiopropyl)- 4-[(l-triphenylmethyl)-4-imidazolylmethyl]aminobenzamide Starting with the product from Step C (0.07 g) the method described in Step D of Example 1 was used to prepare the title compound.
Step E: Preparation of N-(1 (S)-carbomethoxy-3-methylthiopropyl)- 4 4 -imidazolylmethyl)aminobenzamide dihvdrochloride Starting with the product from Step D (0.24 g) the method described in Step E of Example 1 was used to prepare the title compound.
FAB mas spectrum m/e 363 Analysis for C17H22N403S 2.8 HC1: WO 96/30015 PCTIUS96/03980 -82- Calculated: C, 43.99; H, 5.39; N, 12.07; Found: C, 43.94; H, 5.37; N, 12.24.
Step F: Preparation of N-(1(S)-carboxy-3-methylthiopropyl)-4-[(4imidazolylmethyl)aminolbenzamide dihydrochloride Starting with (0.035 g) the method described in Step F of Example 1 was used to prepare the title compound.
m/e 349 Analysis for C16H20N403S 3.10 HC1 1.2 Calculated: C, 39.91; H, 5.13; N, 11.63; Found: C, 39.87; H, 5.12; N, 11.22.
FAB mas spectrum Using the appropriate starting materials the methods described above for Example 4 were used to prepare Examples 5-7.
EXAMPLE N-(1(S)-carboxy-3-methylthiopropyl)-3-[(4-imidazolylmethyl) amino] benzamide dihydrochloride FAB mass spectrum m/e 349 Analysis for C16H20N403S 3.2 HC1: Calculated: C, 41.37; H, 5.03; N, 12.06; Found: C, 41.32; H, 4.92; N, 11.69.
WO 96/30015 WO 9630015PCTIUS96/03980 83 EXAMPLE 6 N-(l1(S)-carbomethoxy-3-methylthiopropyl)-3-[(4-imidazolylpropyl) aminolbenzamide dihydrochioride FAB mass spectrum mle 391 1).
Analysis for C19H26N403S 2.4 HCl 1.3 Calculated: C, 45.53; H, 6.23; N, 11. 18; Found: C, 45.5 1; H, 6.25; N, 11. EXAMPLE 7 1(S)-Carboxy-3-methylthiopropyl)-3-[(4-imidazolylpropyl) amino] benzamide dihydrochioride FAB mass spectrum m/e 377 Analysis for C18H24N403S 3.0 HCl 0.5 Calculated: C, 43.73; H, 5.7 1; N, 11.33; Found: C, 43.67; H, 5.7 1; N, 10.72.
EXAMPLE 8 1(S)-Carboxy-3-methylthiopropyl)-3- [N-(4-imiidazolylymethyl)-N-(4nitrobenzylaminomethyllbenzamide ditrifluoroacetate Step A: N- (1(S)-Carbomethoxy-3-methylthiopropyl)-3- imidazolylymethyl)-N-(4-nitrobenzyl)aininomethyl]benzamide ditrifluoroacetate 1(S)-carbomethoxy-3-methylthiopropyl)-3aminomethylbenzamide (0.104 g, 0.352 mmol) was dissolved in dichioroethane (5 mL). Crushed molecular sieves 0.209 g) and sodium triacetoxyborohydride, (0.186 g, 0.88 1 mmol). The pH was about 7.5. 4- Nitrobenzaldehyde (0.0533 g, 0.352 mmol) was added plus 0.5 drop of acetic acid to bring the pH to about 7. The reaction was stirred 2 h under WO 96/30015 PCT/US96/03980 -84nitrogen at 20 0 C. 1-Triphenylmethylimidazolyly-4-carboxaldehyde (0.119 g, 0.352 mmol) was added to the reaction mixture with additional sodium triacetoxyborohydride and dichloroethane (2 mL). Triethylamine drops) brought the pH to about 7. The reaction continued to stir at 20 0 C under nitrogen overnight. The reaction was quenched with saturated sodium bicarbonate solution and let stir 20 min. It was then removed to a separatory funnel with copious amounts of ethyl acetate.
The aqueous layer was removed and the organic phase was washed with saturated brine and dried over magnesium sulfate. The crude product was chromatographed on silica gel with 50% ethyl acetate in hexane. This chromatographed product was dissolved in dichloromethane 7 mL); triethylsilane (0.5 mL, 3.13 mmol) was added and then trifluoroacetic acid 3.5 mL). After 0.5 h at 20 0 C, the solvent was evaporated and the residue partitioned between hexane and water. The aqueous solution was purified by preparative reverse phase HPLC using a 100 mm Waters PrepPak® reverse phase column (DeltaPak T C18, 50gM, 100 A) and pure product isolated by gradient elution using 80% 0.1% trifluoroacetic acid in water (Solvent A) and 20% 0.1% trifluoroacetic acid in acetonitrile (Solvent B) to 55% Solvent A and 45% Solvent B. The pure fractions were combined and the solvent evaporated, and the pure product was dissolved in water and lyophilized to give the title compound as a clear, pale yellow solid. 1 HNMR (CD30D, 400 MHz) 8 8.78 (1H, br s), 8.18 (2H, d, J=8.6 Hz), 7.86 (1H br 7.74 (1H, br d, J=8 Hz), 7.64 (2H, d, J=8.6 Hz), 7.56 (1H, br d, J=8 Hz), 7.46 (1H, br 7.44 (1H, dd J=8, 8 Hz), 4.8 (1H, 3.74 to 3.79 (9H, 2.58 to 2.66 (2H, 2.23 (1H, 2.12 (1H, 2.10 (3H, FAB ms 512. Anal. Calc. for C25H29N505S 0.70 H20 3.30 TFA. Found: C, 42.12; H, 3.75, N, 7.91.
Step B: Preparation of N-(1(S)-carboxy-3-methylthiopropyl)-3-[N- 4 -imidazolylymethyl)-N-(4-nitrobenzyl)aminomethyl]benzamide ditrifluoroacetate The product from Step A 0.045 g, 0.0608 mmol) was dissolved in methanol (4 mL) and 0.5 mL of 10% NaOH solution was WO 96/30015 PCT/US96/03980 added to take pH to about 12. Water (4 mL) was added. At 3 h reaction was purified and lyophilized according to the procedure described in Step A to the title compound as a white solid. 1 HNMR (CD30D, 400 MHz) 8 8.78 (1H, br 8.18 (2H, d, J=8.6 Hz), 7.88 (1H, br 7.75 (1H, br d, J=8 Hz), 7.65 (2H, d, J=8.6 Hz), 7.55 (1H, br d, J=8 Hz), 7.46 (1H, br s), 7.43 (1H, dd, J=8, 8 Hz), 4.8 (1H, 3.80 (4H, br 3.75 (2H, br s), 2.58 to 2.68 (2H, 2.27 (1H, 2.13 (1H, 2.11 (3H, FAB ms 498, Anal Calc. for C24H27N505S 1.40 H20 3.20 TFA.
Found: C, 41.16; H, 3.72; N, 8.11.
EXAMPLE 9 N-(1(S)-carboxy-3-methylthiopropyl)-3-[N,N-bis-(4nitrophenylmethyl)aminomethyllbenzamide dihydrochloride Step A: Preparation of N-(1 (S)-carboxymethyl-3-methylthiopropyl)- 3-[N.N-bis-(4-nitrophenylmethvl)1 ditrifluoroacetate The product from Example 1, Step 3 (0.100 g, 0.337 mmol) was dissolved in dichloroethane (5 mL). p-Nitrobenzaldehyde, sodium triacetoxyborohydride (0.214 g, 1.01 mmol) and crushed molecular sieves were added, and the pH adjusted to 5.5 with acetic acid and triethylamine. The reaction was stirred at 20 0 C overnight, quenched with saturated sodium bicarbonate, and partitioned between ethyl acetate and saturated sodium bicarbonate. The organic phase was washed with 2% potassium hydrogen sulfate, saturated sodium bicarbonate, saturated brine, and dried over magnesium sulfate. The crude product was purified by silica gel chromatography using 40% ethyl acetate in hexane. This product was further purified by preparative reverse phase HPLC using a gradient elution from 85% water, 15% acetonitrile to 20% water over a period of 40 min. (solvents contained 0.1% trifluoroacetic acid).
1 HNMR (300 MHz, CDC13) d 8.25(4H, d, J=8.5 Hz), 7.92 (1H, 7.80 (1H, d, J=7.6 Hz), 7.63 (4H, d, J=8.5 Hz).7.53 2H), 7.35 (1H, d, J=7.3 Hz), 4.94 (1H, bq, J=6.2 Hz), 3.98 (4H, 3.95 (2H, 3.82 (3H, 2.61 (2H, t, J=7.3 Hz), 2.30 (1H, 2.19 (1H, dt, J=15, 7.5 Hz), 2.11 WO 96/30015 PCTIUS96/03980 -86- (3H, Analysis calculated for C28H30N407S 2.1 CF3CO2H C,47.45; H, 4.09; N, 6.87. Found: C, 47.44; H, 4.01; N, 6.91.
Step B: Preparation of N-(1 (S)-carboxy-3-methylthiopropyl)-3- [N,N-bis-(4-nitrophenylmethyl)aminomethyl]benzamide ditrifluoroacetate The product from Step 1 (0.025 g) was hydrolyzed to the acid according to the procedure described in Example 1, Step 6. The title compound was obtained after purification by preparative reverse phase HPLC. FAB ms m/e 553). Analysis calculated for C27H28N407S 1.6 CF3CO2H 0.2 H20: C, 49.11; H, 4.09; N, 7.59.
Found: C, 49.10; H, 3.93; N, 7.55.
EXAMPLE In vitro inhibition of ras farnesyl transferase Assays offarnesyl-protein transferase. Partially purified bovine FPTase and Ras peptides (Ras-CVLS, Ras-CVIM and RAS-CAIL) were prepared as described by Schaber et al., J. Biol. Chem. 265:14701-14704 (1990), Pompliano, et al., Biochemistry 31:3800 (1992) and Gibbs et al., PNAS U.S.A. 86:6630-6634 (1989), respectively. Bovine FPTase was assayed in a volume of 100 tl containing 100 mM N-(2-hydroxy ethyl) piperazine-N'-(2-ethane sulfonic acid) (HEPES), pH 7.4, 5 mM MgC12, mM dithiothreitol (DTT), 100 mM 3 H]-faresyl diphosphate 3
H]-FPP;
740 CBq/mmol, New England Nuclear), 650 nM Ras-CVLS and gg/ml FPTase at 310C for 60 min. Reactions were initiated with FPTase and stopped with 1 ml of 1.0 M HCL in ethanol. Precipitates were collected onto filter-mats using a TomTec Mach II cell harvestor, washed with 100% ethanol, dried and counted in an LKB (-plate counter. The assay was linear with respect to both substrates, FPTase levels and time; less than 10% of the 3 H]-FPP was utilized during the reaction period.
Purified compounds were dissolved in 100% dimethyl sulfoxide (DMSO) and were diluted 20-fold into the assay. Percentage inhibition is measured by the amount of incorporation of radioactivity in the presence WO 96/30015 PCTIUS96/03980 -87of the test compound when compared to the amount of incorporation in the absence of the test compound.
Human FPTase was prepared as described by Omer et al., Biochemistry 32:5167-5176 (1993). Human FPTase activity was assayed as described above with the exception that 0.1% polyethylene glycol 20,000, 10 LM ZnC12 and 100 nM Ras-CVIM were added to the reaction mixture. Reactions were performed for 30 min., stopped with 100 gl of 30% trichloroacetic acid (TCA) in ethanol and processed as described above for the bovine enzyme.
The compounds of the instant invention were tested for inhibitory activity against human FPTase by the assay described above and were found to have IC50 of 100 gM.
EXAMPLE 11 In vivo ras farnesylation assay The cell line used in this assay is a v-ras line derived from either Rat or NIH3T3 cells, which expressed viral Ha-ras p21. The assay is performed essentially as described in DeClue, J.E. et al., Cancer Research 51:712-717, (1991). Cells in 10 cm dishes at 50-75% confluency are treated with the test compound (final concentration of solvent, methanol or dimethyl sulfoxide, is After 4 hours at 37 0
C,
the cells are labelled in 3 ml methionine-free DMEM supple-meted with regular DMEM, 2% fetal bovine serum and 400 mCi[ 3 5 S]methionine (1000 Ci/mmol). After an additional 20 hours, the cells are lysed in 1 ml lysis buffer NP40/20 mM HEPES, pH 7.5/5 mM MgCl2/lmM DTT/10 mg/ml aprotinen/2 mg/ml leupeptin/2 mg/ml mM PMSF) and the lysates cleared by centrifugation at 100,000 x g for 45 min. Aliquots of lysates containing equal numbers of acid-precipitable counts are bought to 1 ml with IP buffer (lysis buffer lacking DTT) and immunoprecipitated with the ras-specific monoclonal antibody Y13-259 (Furth, M.E. et al., J. Virol. 43:294-304, (1982)).
Following a 2 hour antibody incubation at 4 0 C, 200 ml of a suspension of protein A-Sepharose coated with rabbit anti rat IgG is WO 96/30015 PCT/US96/03980 -88added for 45 min. The immunoprecipitates are washed four times with IP buffer (20 nM HEPES, pH 7.5/1 mM EDTA/1% Triton X-100.0.5% deoxycholate/0.1%/SDS/0.1 M NaC1) boiled in SDS-PAGE sample buffer and loaded on 13% acrylamide gels. When the dye front reached the bottom, the gel is fixed, soaked in Enlightening, dried and autoradiographed. The intensities of the bands corresponding to farnesylated and nonfaresylated ras proteins are compared to determine the percent inhibition of farnesyl transfer to protein.
EXAMPLE 12 In vivo growth inhibition assay To determine the biological consequences of FPTase inhibition, the effect of the compounds of the instant invention on the anchorage-independent growth of Ratl cells transformed with either a vras, v-raf, or v-mos oncogene is tested. Cells transformed by v-Raf and v-Mos maybe included in the analysis to evaluate the specificity of instant compounds for Ras-induced cell transformation.
Rat 1 cells transformed with either v-ras, v-raf, or v-mos are seeded at a density of 1 x 104 cells per plate (35 mm in diameter) in a 0.3% top agarose layer in medium A (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum) over a bottom agarose layer Both layers contain 0.1% methanol or an appropriate concentration of the instant compound (dissolved in methanol at 1000 times the final concentration used in the assay). The cells are fed twice weekly with 0.5 ml of medium A containing 0.1% methanol or the concentration of the instant compound. Photomicrographs are taken 16 days after the cultures are seeded and comparisons are made.

Claims (8)

  1. 2. A prodrug of the compound of Claim 1 having the Z R 3 a a R3b R4 OR 6 N-(CR N H 0 R2a R 2 b II wherein: Rla and Rib are independently selected from: a) hydrogen, WO 96/300 15 PCr1US96103980 -93 b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, R 10 0-, R 1 IS(O)m-, Rl 0 C(O)NRIO-, CN, N02, (RI 0 )2N-C(NRl Ri RI 0 N3, -N(RI 0)2, or R I IOC(O)NR C) CI-C6 alkyl. unsubstituted or substituted by aryl, heterocyclic, cycloalkyl, aikenyl, alkynyl, RIO0-, RI IS(O)m-, RlOC(O)NR10-, CN, (Rl 0 )2N-C(NRlO)-, RlOC(O)-, RIO0C(O)-, N3, -N(RlO)2, or R1 I0C(O)- NR 1 0.; R2a and R2b are independently selected from: a) hydrogen, b) C I-C6 alkyl unsubstituted or substituted by aikenyl, R 1 0 0-, R' 0 R 1 0 -N(RlO)2, or R 1 1 OC(O)NR 1 0-, c) aryl, heterocycle, cycloaikyl, ailkenyl, R 1 0 0-, R 11 RIOC(O)NRIO-, CN, N02, (RIO)2N- C(NRIO)-, RIOC(O)-, RIO0C(O)-, N3, -N(R 1 0 )2, or R IIOC(O)NR 10-, and d) C1I-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3-ClO cycloalkyl; R3a and R3b are independently selected from: a) a side chain of a naturally occurring amino acid, b) an oxidized form of a side chain of a naturally occurrng amino acid which is: i) methionine sulfoxide, or ii) methionine sulfone, and c) substituted or unsubstituted C1I-C20 alkyl, C2-C20 alkenyl, C3-CIO cycloalkyl, aryl. or heterocyclic group, wherein the substituent is selected from F, Cl, Br, N(R 110 N02, R 1 0 R 111 RlOC(O)NR 1 0-, CN, (R 10 2 N-C(NRIO)-, RIOC(O)-, RIO0C(O)-, N 3 -N(R 1 0 2 R 1 1 0C(O)NRIO- and CI-C 20 alkyl, and d) C 1 -C 6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C 3 -CIO cycloalkyl; or R 3 a and R3b are combined to form (CH9A wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, S( 0 and -N(C0RIO)-; R 4 and R 5 are independently selected from: a) hydrogen, and b) R'Hj I I Ia 2 Ia lb V-A (CR a 2 ),A2(CR 2)n W CR 2)p R 6 is a) substituted or unsubstituted CI-C 8 alkyl or substituted or unsubstituted C 5 -C 8 cycloalkyl, wherein the substituent on the alkyl is selected from: 1) aryl, 2) heterocycle, 3) -N(R 11) 2 4) -OR 1 0 or b) R' R 0 200 R 7 is independently selected from: hydrogen, aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R1 0 RIIS(O)m-, [N:\LIBAA1O1 556:TAS WO 96/300 15 PCTUS96O3980 95 RIOC(O)NR 1 CN, N02, R 10 2N-C(NRI Oy., R' 0 N3, -N(RlO)2, or RI 1OC(O)NRIO-, and c) C1I-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R 1 0 RIIS(O)m-, Rl 0 C(O)NH-, CN, H2N- RlOC(O)-, R 10 N3, -N(RlO)2, or R' OOC(O)NH-; R8 is selected from: a) hydrogen, b) alkenyl, alkynyl, perfinoroalkyl, F, Cl, Br, R 1 0 0-, RIIS(O)m-, RIOC(O)NR10-, CN, N02, (R 1 0 )2N-C-(NR10)-, R 1 0 R 10 N3, 102,or R1 1 OC(O)NR 1 and c) C1I-C6 alkyl unsubstituted. or substituted by peffluoroalkyl, F, Cl, Br, R 10 R 1 S R 1 OC(O)NR 10-, CN, (R 1 0 )2N-C(NRl0)-, R 1 Rl OOC(O)-, N3, -N(Rl 0)2, or RI 1 R 10 is independently selected from hydrogen, C1I-C6 alkyl, benzyl and aryl; R 1 1 is independently selected from C1I-C6 ailkyl and aryl; R 12 is independently selected from hydrogen and C1I-C6 alkyl; R 13 is independently selected from ClI-C6 alkyl; A 1 and A 2 are independently selected from: a bond, -CH=CH-, -C=EC-, -C(O)NRIO-, -NRl 0 0, -N(RlO)-, -S(0)2N(R 1 -N(RIO)S(0)2-, or S(O)m; V is selected from: a) hydrogen, WO 96/30015 PCT/US96/03980 -96- b) heterocycle, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if Al is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; Z is independently H2 or O; m is n is pis r is s is u is 0, 1 or 2; 0, 1, 2, 3 or 4; 0, 1, 2, 3 or 4; 0 to 5, provided that r is 0 when V is hydrogen; 4 or 5; and 0or 1; or a pharmaceutically acceptable salt thereof.
  2. 3. A compound which inhibits Ras famesyl-transferase having the Formula III: HOCH 2 (CH 2 )q R "INN R 2 b wherein: Ra and Rlb are independently selected from: WO 96/30015 PCT1US96/03980 97 a) hydrogen, b) aryl, heterocycle, cycloalkyl, aikenyl, alkynyl, R 1 0 0-, R 111 RIOC(O)NRIO-, CN, N02, (Rl 0 )2N-C(NR10).., R 1 0 RI 0 N3, -N(R 10)2, or R1 c) C1I-C6 alkyl unsubstituted or substituted by aryl, heterocyclic, cycloalkyl, alkenyl, alkynyl, RIO0-, R 1 1 S R I OC(O)NR CN, (R 10 )2N-C(NR RIOC(O)-, R10OC(O)-, N3, -N(R 1 0 or R1 I0C(O)- NRIO-; R2a and R2b are independently selected from: a) hydrogen, b) C1I-C6 alkyl unsubstituted or substituted by alkenyl, R 1 0 0-, R 1 1 Rl 0 C(O)NRIO-, CN, N3, (R 1 0 )2N-C(NRIO)-, Rl 0 RIOOC(O)-, or RI 1 0C(O)NRIO-, c) aryl, heterocycle, cycloalkyl, alkenyl, RIO0-, RIIS(O)m-, Rl 0 C(O)NR10-, CN, N02, (R 1 0 )2N-C(NR10)-, R 10 R 1 OOC(O)-, N3, -N(R 1 0 or R1 1 0C(O)NRIO-, and d) C I-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3-C10 cycloalkyl; R 4 and R5 are independently selected from: a) hydrogen, and b) (R )r R8 V Al(CRla 2 )nA 2 (CRla 2 )n kW,- (CR1b 2 R7 is independently selected from: a) hydrogen, WO 96/30015 PCT1US96103980 98 b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroaikyl, F, Cl, Br, RIO0-, RI lS(O)m-, RIOC(O)NRIO-, CN, N02, RlO2N-C(NRl0)-, RIOC(O)-, RIO0C(O)-, N3, or Rl I0C(O)NRIO-, and c) C I-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalcyl, F, Cl, Br, R 10 R 1 1 Rl 0 C(O)NH-, CN, H2N-C(NH)-, RIOC(O)-, RIO0C(O)-, N3, -N(RlO)2, or Ri 0 0C(O)NH-; R8 is selected from: a) hydrogen, b) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R 10 0-, R' 1 R I C(O)NR 10-, CN, N02, (R 1 O)2N-C- Rl 0 RlO0C(O)-, N3, -N(RIO)2, or RII0C(O)NRIO-, and c) Cl-C6 alkyl unsubstituted or substituted by peffluoroalkyl, F, Cl, Br, RIO0-, Rl lS(O)m-, RIOC(O)NRlO-, CN, (RI 0 )2N-C(NRl0)-, R 10 R 1 OOC(O)-, N3, -N(Rl 0)2, orRIIOC(O)NRIO-;, RIO is independently selected from hydrogen, Cl-C6 alkyl, benzyl and aryl; R I is independently selected from ClI-C6 alkyl and aryl; A 1 I and A 2 are independently selected from: a bond, -CH=CH-, -CR=C-, -C(O)NRIO-, -NRIOC(O)-, 0, -N(RIO)-, -S(0)2N(RIO)-, -N(RlO)S(0)2-, or S(O)m; V is selected from: a) hydrogen, b) heterocycle, c) aryl, WO 96/30015 PCTfUS96/03980 -99- d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if Al is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; Z is independently H2 or O; m is n is p is q is ris s is u is 0, 1 or 2; 0, 1, 2, 3 or 4; 0, 1,2, 3 or 4; 0, 1 or 2; 0 to 5, provided that r is 0 when V is hydrogen; 4 or 5; and 0 or 1; or a pharmaceutically acceptable salt thereof.
  3. 4. A prodrug of the compound of Claim 3 having the Formula IV: R 2 b wherein: Rla and Rib are independently selected from: a) hydrogen, WO 96/30015 PCTUS96Io398o -100- b) aryl, heterocycle, cycloaikyl, alkenyl, alkynyl, R 10 0-, Rl 1 RIOC(O)NRIO-, CN, N02, (R 10 )2N-C(NR 1 R 10 R lOOC(O)-, N3, -N(R 10)2, or Rl c) C I -C6 ailkyl unsubstituted or substituted by aryl, heterocyclic, cycloalkyl, alkenyl, alkynyl, R 1 0 0-, RIOC(O)-, RIO0C(O)-, N3, -N(RIO)2, or R 1 1 0C(O)- R2a and R2b are independently selected from: a) hydrogen, b) C1I-C6 alkyl unsubstituted or substituted by alkenyl, R 100-, R 1 R 1 (IC(O)NRi CN, N3, 0 )2N-C(NR RIOC(O)-, RIO0C(O)-, -N(RIO)2, or RI 1 OC(O)NR 1 0-, c) aryl, heterocycle, cycloalkyl, alkenyl, RIO0-, R 11 RIOC(O)NRIO-, CN, N02, (Ri 0 )2N-C(NRl0)-, R 1 0 RI 0 N3, -N(RIO)2, or RI 1 0C(O)NR 1 and d) C1-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3-C10 cycloalkyl; R 4 and R5 are independently selected from: a) hydrogen, and b) (R )r R8 V A 1 (CRa a 2 2 (CRla 2 kW,-(C R b 2 R7 is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R 1 0 R1 1 WO 96/300 15 PCT/US96103980 101 R 1 0 C(O)NR 1 CN, N02, R' 0 2N-C(NR10)-, RI 0 R 10 N3, or RI 1 0C(O)NRlO-, and c) Cl-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, aikynyl, pertluoroalkyl, F, Cl, Br, R 1 0 RI IS(O)m-, RIOC(O)NH-, CN, H2N- RIOC(O)-, R 10 N3, -N(RlO)2, or R 1 0 0C(O)NH-; R8 is selected from: a) hydrogen, b) alkenyl, alkynyl, peffluoroatkyl, F, Cl, Br, RIO0-, Rl 1 Rl 0 C(O)NR10-, CN, N02, (RI 0 )2N-C-(NRIO)-, Ri RIO0C(O)-, N3, 102,or R I IOC(O)NR 10-, and C) C I-C6 alkyl unsubstituted or substituted by peffluoroalkyl, F, Cl, Br, R 1 0 R 1 1 RIOC(O)NRIO-, CN, (Rl 0 )2N-C(NRIO)-, RIOC(O)-, RIO0C(O)-, N3, -N(R'O)2, or R' IIOC(O)NR R 1 0 is independently selected from hydrogen, C1I-C6 alkyl, benzyl and aryl; R I is independently selected from C1I-C6 alkyl and aryl; Al and A 2 are independently selected from: .a bond, -CH=CH-, -C(O)NR10-, -NRIOC(O)-, 0, -N(RlO)-, -S(0)2N(RIO)-, -N(Rlo)S(0)2-, or S(O)m; V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) ClI -C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom. selected from 0, S, and N, and WO 96/30015 PCT/US96/03980 -102- e) C2-C20 alkenyl, provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; Z is independently H2 or O; m is 0, 1 or 2; nis 0,1, 2, 3 or 4; pis 0,1, 2, 3 or4; q is 0, 1 or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 4 or 5; and uis 0orl; or a pharmaceutically acceptable salt thereof. The compound according to Claim 1 of the formula Ia: R 4 Z R 3 R 3 b \N (CRlb2)p OH H 0 R2 a R 2 b la wherein: Ra is independently selected from: hydrogen or C1-C6 alkyl; Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R100-, -N(R 10 )2 or alkenyl, WO 96/30015 WO 960015PTAJS96I03980 103 C) Cl-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, RIO0-, or NRO2 R2a is selected from: a) hydrogen, b) C 1-C6 alkyl unsubstituted or substituted by alkenyl, R 1 0 0-, R 1 1 S(O)m7-, Rl 0 C(O)NR1 0 CN, N3, (R' 0 )2N-C(NRIO)-, RlOC(O)-, R10OC(O)-, -N(Rl 0 or c) aryl, heterocycle, cycloalkyl, alkenyl, R 1 0 0-, R 1 1 Rl 0 C(O)NRIO-, CN, N02, (R 1 0 )2N-C(NRIO)-, R 1 R 1 OOC(O)-, N3, -N(R0)2,or R 1 IOC(O)NRIO-, and d) Cl1-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3- C R2b is hydrogen; R3a and RRb are independently selected from: a) a side chain of a naturally occurring amino acid, b) an oxidized form of a side chain of a naturally occurring amino acid which is: i) methionine sulfoxide, or ii) methionine sulfone, c) substituted or unsubstituted Cl1-Cl 10 alkyl, C2-C 10 alkenyl., C3-C1O cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, N02, RIO0-, R 1 1 Rl 0 C(O)NR10-, CN, (Rl 0 )2N-C(NR 10 R 1 R' OOC(O)-, N3, -N(Rl 0 R1 lOC(O)NR10- and C1-C20 alkyl, and d) Ci -C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C3- Cl1o cycloalkyl; WO 96/30015 WO 9630015PCTIUS96/03990 -104- R 4 and R5 are independently selected from: a) hydrogen, and (R )r R8z -Al(CRla 2 ),A 2 (CRla) (CRb)(/ R 7 is independently selected from: a) hydrogen, b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 1 0 RlOC(O)NR10-, CN, N02, (RIO)2N-C(NR 10 RIOC(O)-, R10OC(O)-, -N(Rl 0 or R 1 1 0C(O)NR 10 and C) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 10 0-, RlOC(O)NR 10 (RlO)2N-C(NRIO)-, RlOC(O)-, -N(R 1 0 or Rl 1 OC(O)NR 1 0-; R 8 is selected from: a) hydrogen, b) C2-C6 alcenyl, C2-C6 alcynyl, C 1-C6 peffluoroalkyl, F, Cl, R 10 R 1 1 RIOC(O)NR1 0 CN, N02, (Ri O)2N-C(NR 1 Ri R 1 OOC(O)-, -N(Rl 0)2, or Rl 1 OC(O)NR 10 and C) C 1-C6 alkyl unsubstituted or substituted by C 1-C6 peffluoroalkyl, F, Cl, R 100-, R 1 S RIOC(O)NR 1 0 CN, (RIO)2N-C(NR 10 R 1 R lOOC(O)-, -N(Rl 0)2, or RI IOC(O)NR 1 0 R 10 is independently selected from hydrogen, C 1-C6 alkyl, benzyl and aryl; R 1 1 is independently selected from C1-C6 alkyl and aryl; A 1 l and A 2 are independently selected from: a bond, -CH=CH-, -C WO 96/30015 PCTIUS96/03980 -105- -C(O)NR10-, O, or S(O)m; V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or isoquinolinyl; Z is independently H2 or O; m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; pis 0,1, 2, 3 or 4; r is 0 to 5, provided that r is 0 when V is hydrogen; and uis Oor 1; or a pharmaceutically acceptable salt thereof.
  4. 6. The compound according to Claim 2 of the formula IIa: WO 96/30015 PCTIUS96rj3980
  5. 106- R 4 Z R 3 R3b RVN (CRlb 2 )p N OR 6 Ila Ri1a is independently selected from: hydrogen or C1I-C6 alkyl; Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10 -N(R 10)2 Or alkenyl, c) C1I-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, RlO0-, or -N(RIO)2; R2a is selected from: a) hydrogen, b) C I-C6 alkyl unsubstituted or substituted by alkenyl, R 1 0 0-, RIIS(0)m-, RIOC(O)NRIO-, CN, N3, (RIO)2N-C(NR1O)-, RIOC(0)-, RIO0C(O)-, or RI I0C(0)NRIO-, c) aryl, heterocycle, cycloalkyl, ailkenyl, Rl 0 0-, RI 1 R 1 0 C(0)NR1O-, CN, N02, (R' 0 )2N- C(NR 1 R' RI 0 N3, -N(R 10)2, or R I IOC(O)NR 1 and d) C I-C6 alkyl. substituted with an unsubstituted. or substituted group selected from aryl, heterocyclic and C3- C 10 cycloallcyl; R2b is hydrogen; R3a and R3b are independently selected from: a) a side chain of a naturally occurring amino acid, b) an oxidized form of a side chain of a naturally occurring amino acid which is: WO 96/30015 PCT1US96/03980 -107- i) methionine sulfoxide, or ii) methionine sulfone, c) substituted or unsubstituted Cl-C 10 alkyl, C2-ClO alkenyl, C3-C 10 cycloallcyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, N02, R 10 Rl 1 Rl 0 C(O)NR10-, CN, -N(R 10)2, Ri 11OC(O)NR 10- and C1I-C20 alkyl, and d) C I -C6 alkyl substituted with an unsubstituted. or substituted group selected from aryl, heterocycle and C3- cycloalkyl; R 4 and R5 are independently selected from: a) hydrogen, and b) R 6 is a) substituted or unsubstituted C1I-C8 alkyl or substituted or unsubstituted C5-C8 cycloalkyl, wherein the substituent on the alkyl is selected from: 1) aryl, 2) heterocycle, 3) -N(R 1 1 )2, 4) -OR10, or WO 96/30015 WO 96/00 15PCTIUS96/03990 -108- b) R 1 2 o \z 0 R'1 3 R 7 is independently selected from: a) hydrogen, b) C 1-C6 alkyl, C2-C6 aikenyl, C2-C6 alkynyl, ClI-C6 peffluoroalcyl, F, Cl, R 10 RIOC(O)NRIO-, CN, N02, (RIO)2N-C(NR 1 RIOC(0)-, RIO0C(O)-, -N(RIO)2, or R 1 1 OC(O)NRIO-, and c) C1I-C6 alkyl substituted by C1I-C6 periluoroalkyl, R 1 0 0-, R 1 OC(O)NRi (RIO)2N-C(NRiO)-, R 1 OC(O)-, R' OOC(0)-, -N(Rl 0)2, or RIIOC(0)NR R8 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 peffluoroalkyl, F, Cl, R 10 RIIS(O)mn-, RIOC(0)NR10-, CN, N02, (R 10 )2N-C(NR R 1 R 1 0 -N(R 10)2, or R11OC(O)NRIO-, and c) C 1-C6 alkyl unsubstituted or substituted by C 1-C6 peffluoroalkyl, F, Cl, R1 0 Rl 1 Rl 0 C(O)NRIO-, CN, (R 10 )2N-C(NR10).., R lOC(O)-, R 1 0 -N(Rl 0)2, or R 10 is independently selected from hydrogen, C 1-C6 alkyl, benzyl and aryl; R 1 is independently selected from C 1-C6 alkyl and aryl; R 12 is independently selected from hydrogen and C1-C6 alkyl; R 13 is independently selected from C1-C6 alkyl; WO 96/30015 PCT/US96/03980 -109- Al and A 2 are independently selected from: a bond, -CH=CH-, -C(O)NR10-, O, or S(O)m; V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or isoquinolinyl; Z is independently H2 or O; m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; r is 0 to 5, provided that r is 0 when V is hydrogen; and uis 0orl; or a pharmaceutically acceptable salt thereof. 7. The compound according to Claim 3 of the formula IIIa: F WO 96130015 PCTIUS96/03980 -110- HOCH 2 (CH 2 )q R 4 z N CR~b2)pOH N 132a/ R 2 b Ilila wherein: R Ia is independently selected from: hydrogen or C1I-C6 alkyl; Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R100-, -N(R 1 0 )2 or alkenyl, c) C1I-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, R 10 or NRO2 R2a is selected from: a) hydrogen, b) C 1-C6 alkyl unsubstituted or substituted by alkenyl, R 1 0 0-, R1 1 R 1 C(O)NR 10-, CN, N3, (RI 0 )2N-C(NR 10 RlOC(O)-, R 10 -N(RIO)2, or Rl c) aryl, heterocycle, cycloalkyl, alkenyl, R 10 0-, R 1 IS(O)m-, RIOC(O)NR 1 CN, N02, (Rl 0 )2N- C(NRIO)-, RIOC(O)-, RIOOC(O)-, N3, -N(Rl 0 )2, or R1 I0C(O)NR10-, and d) C1-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3- C 1 cycloalkyl; R2b is hydrogen; R 4 and R5 are independently selected from: a) hydrogen, and I WO 96/30015 WO 9630015PCTIUS96/03980 b) (R )r R8 2 R 7 is independently selected from: a) hydrogen, b) C 1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1I-C6 perfluoroalkyl, F, Cl, R100-, RlOC(O)NRIO-, CN, N02, (Rlo)2N-C(NR'%-, RlOC(O)-, R10OC(O)-, -N(R 1 0 or R11OC(O)NR 1 0 and c) C 1-C6 ailkyl substituted by ClI-C6 perfluoroalkyl, R 100-, RlOC(O)NR 10 (RI 0 )2N-C(NR 1 RlOC(O)-, R 10 -N(R 1 0 or R 1 1 0C(O)NR 1 R8 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, Cl1-C6 peffluoroalkyl, F, Cl, R 10 R 1 1 Rl 0 C(O)NRIO-, CN, N02, (RIO)2N-C(NR 10 RlOC(O)-, R10OC(O)-, -N(RIO)2, or R1 IOC(O)NR 10 and C) C 1-C6 alkyl unsubstituted or substituted by C 1-C6 peffluoroalkyl, F, Cl, R 1 0 R 1 1 Rl 0 C(O)NRIO-, CN, (RlO)2N-C(NR' 0 R 1 R10OC(O)-, -N(Rl 0)2, or RI R 1 0 is independently selected from hydrogen, C I-C6 alkyl, benzyl and aryl; R 1 is independently selected from ClI-C6 alkyl and aryl; Al and A 2 are independently selected from: a bond, -CH=CH-, -C(O)NR 10 0, or S(O)m; WO 96/30015 PCT/US96/03980 -112- V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if Al is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or isoquinolinyl; Z is independently H2 or O; mis 0, 1 or 2; nis 0,1, 2, 3 or 4; pis 0,1, 2, 3 or 4; q is 0, 1 or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; and uis 0or 1; or a pharmaceutically acceptable salt thereof. 8. The compound according to Claim 4 of the formula IVa: WO 96/30015 WO 96/00 15PCTIUS96103980 113 N -(CRlb 2 )C IVa R 2 -KR 2 b wherein: Ria is independently selected from: hydrogen or C1-C6 alkyl; Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, RIOO-, -N(RIO)2 or alkenyl, c) C 1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, RIO0-, or NRO2 R2a is selected from: a) hydrogen, b) C1I-C6 ailkyl unsubstituted or substituted by alkenyl, R 1 0 0-, R1 1 Rl 0 C(O)NR 1 0 CN, N3, (Rl 0 )2N-C(NR 10 RlOC(O)-, RIOOC(O)-, -N(Rl 0 or R1 1OC(O)NR 1 0-, c) aryl, heterocycle, cycloalkyl, alkenyl, R 10 0-, RI 1 Rl 0 C(O)NRIO-, CN, N02, (RlO)2N-C(NR 1 R 1 R 1 OOC(O)-, N3, -N(R 1 0 or R1 1 OC(O)NR 10-, and d) C1I-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3- CG1 cycloalkyl; R2b is hydrogen; R 4 and R5 are independently selected from: a) hydrogen, and I WO 96/30015 W096/0015PCT/US96/03980 -114- b) V -A'CR2 CR2 (CR b 2 R 7 is independently selected from: a) hydrogen, b) C 1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C I-C6 perfluoroalkyl, F, Cl, R 10 RIOC(O)NR10-, CN, N02, (Rl 0 )2N-C(NR 1 Rl R lOOC(O)-, -N(Rl 0)2, or RI IOC(O)NR 1 and c) C 1-C6 alkyl substituted by ClI-C6 perfluoroalkyl, R 100-, Ri OC(O)NR 1 (Rl 0 )2N-C(NRI RIOC(O)-, R 1OOC(O)-, -N(R 10 or Ri 11OC(O)NR10-; R 8 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, C I-C6 perfiuoroalkyl, F, Cl, R 10 R 11 Rl 0 C(O)NR10-, CN, N02, (Rl 0 )2N-C(NR 1 0 R 1 Ri OOC(O)-, -N(Ri 0)2, or R 1 iOC(O)NRiO-, and C) Ci1 -C6 alkyl unsubstituted or substituted by C I -C6 perfluoroalkyl, F, Cl, R 1 0 R1 1 R I C(O)NR 1 0-, CN, (RIO)2N-C(NR 1 RIOC(O)-, R10OC(O)-, -N(Rl 0 )2, or R1 Ri10 is independently selected from hydrogen, Ci1-C6 alkyl, benzyl and aryl; Rl I is independently selected from C I-C6 ailkyl and aryl; A 1 l and A 2 are independently selected from: a bond, -CH=CH-, -C.EC-, -C(O)NR10-, 0, or S(O)m; I WO 96/30015 PCT/US96/03980
  6. 115- V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(0)m; W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or isoquinolinyl; Z is independently H2 or O; m is nis p is q is r is u is 0, 1 or 2; 0, 1, 2, 3 or 4; 0, 1, 2, 3 or 4; 0, 1 or 2; 0 to 5, provided that r is 0 when V is hydrogen; and Oor 1; or a pharmaceutically acceptable salt thereof. 9. A compound which inhibits farnesyl-protein transferase which is: N-(1(S)-carboxy-3-methylthiopropyl)-3-(4-imidazolylmethyl)- aminomethylbenzamide WO096130015 PTU9/38 PCT/US96/03980 -116- 1 (S)-carboxy-3-methylthiopropyl)-3 -[N,N-bis-(4-imidazole- methyl)aniinomethyl]benzaniide 1(S)-carboxy-3-methylthiopropyl) 3- [(4-imidazolylmethyl) -N- methylaminomethyl]benzamide 1(S)-carboxy-3-methylthiopropyl) 4- [(4-imidazolylmethyl)- amino]benzamide N-(l1(S)-carboxy-3-methylthiopropyl)-3- [(4-imidazolylmethyl) amino] benzaniide N-(l1(S)-Carboxy-3-methylthiopropyl)-3-[(4-imidazolylpropyl) amino] benzaxnide N-(l1(S)-Carboxy-3-methylthiopropyl)-3- [N-(4-imidazolylymethyl)-N-(4- nitrobenzyl)aminomethyl]benzamnide N-(l1(S)-carboxy-3 -methylthiopropyl)-3- [N,N-bis-(4- nitrophenylmethyl)aminomethyl]benzamide or N-(l1(S)-carbomethoxy-3-methylthiopropyl)-3-(4-imidazolylmethyl.. aminomethylbenzamide 1 (S)-carbomethoxy-3-methylthiopropyl)-3- [N,N-bis-(4-imidazole- methyl)aminomethyl]benzamide 1(S)-carbomethoxy-3-methylthiopropyl) 3- [(4-imidazolylmethyl) -N- methylamninomethyl]benzamide 1(S)-carbomethoxy-3-methylthiopropyl) 4- [(4-imidazolylmethyl)- amino]benzamide WO 96/30015 WO 9630015PCTfUS96/03980
  7. 117- 1 (S)-carbomethoxy-3-methylthiopropyl)-3- [(4-inildazolylmethyl) amino] benzamide N-(l1(S)-carbomethoxy-3-methylthiopropyl)-3- [(4-imidazolyipropyl) amino]benzamide 1(S)-Carbomethoxy-3-methylthiopropyl)-3-[N-(4- imidazolylymethyl)-N-(4-nitrobenzyl)aminomethyl]benzamide 1(S)-carbomethoxy-3-methylthiopropyl)-3- [N,N-bis-(4- nitrophenylmethyl)aminomethyl]benzamide or a pharmaceutically acceptable salt thereof. 10. A compound according to Claim 9 which inhibits farnesyl-protein transferase which is: 1(S)-carboxy-3-methylthiopropyl)-3- [N,N-bis-(4- nitrophenylmethyl)] aminomethylbenzan-ide H3C, S .OH 0 2 N or a pharmaceutically acceptable salt thereof. 11. A compound according to Claim 9 which inhibits farnesyl-protein transferase which is: 1(S)-carbomethoxy-3-methylthiopropyl)-3- [N,N-bis-(4- nitrophenylmethyl)aminomethyl]benzamide WO 96/30015 WO 9630015PCT/US96/03980 -118- H3C...S 0 N OCH 3 H-1 0 0 2 N or a pharmaceutically acceptable salt thereof. 12. A compound according to Claim 9 which inhibits farnesyl-protein transferase which is: N-(l1(S)-carboxy-3-methylthiopropyl)-3-[N,N-bis(4-imidazole- methyl)aminomethyl] benzamide H H 3 C.. N s N- 0 I- I OH N N HN N or a pharmaceutically acceptable salt thereof. 13. A compound according to Claim 9 which inhibits farnesyl-protein transferase which is: 1(S)-carbomethoxy-3-methylthiopropyl)-3- [N,N-bis(4-imidazole- methyl)aminomethyl] benzamide WO 96130015 PCT/US96/03980
  8. 119- H N HN\ N or a pharmaceutically acceptable salt thereof. 14. A compound according to Claim 9 which inhibits farnesyl-protein transferase which is: 1(S)-Carboxy-3-methylthiopropyl)-3- [N-(4-imidazolylymethyl)-N-(4- nitrobenzyl)aminomethyl]benzamide H 0 2 N or a pharmaceutically acceptable salt thereof. A compound according to Claim 9 which inhibits farnesyl-protein transferase which is: 1(S)-Carbomethoxy-3-methylthiopropyl)-3- imidazolylymethyl)-N-(4-nitrobenzyl)aniinomethyl]benzaniide H H3Cs -N S H 0 2 N" or a pharmaceutically acceptable salt thereof. 16. A compound which inhibits Ras farnesyl-transferase or a prodrug thereof, substantially as hereinbefore described with reference to any one of the Examples. 17. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of any one of claims 1 to 16. 18. A method for inhibiting farnesylation of Ras protein, which method comprises administering to a mammal a therapeutically effective amount of a compound of any one of claims 1 to 16 or of a composition of claim 17. 19. A compound of any one of claims 1 to 16 or a composition of claim 17 when used to inhibit farnesylation of Ras protein in a mammal. 20. Use of a compound of any one of claims 1 to 16 in the manufacture of a medicament for inhibiting farnesylation of Ras protein in a mammal. 15 21. A method for treating cancer, which method comprises administering to a mammal a therapeutically effective amount of a compound of any one of claims 1 to 16 or of a composition of claim 17. 22. A compound of any one of claims 1 to 16 or a composition of claim 17 when used to treat cancer in a mammal. 20 23. Use of a compound of any one of claims 1 to 16 in the manufacture of a medicament for treating cancer in a mammal. Dated 7 April, 1999 Merck Co., Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON [N:\LIBAA]01556:TAB
AU53701/96A 1995-03-29 1996-03-25 Inhibitors of farnesyl-protein transferase Ceased AU706008B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/412,830 US5534537A (en) 1995-03-29 1995-03-29 Prodrugs of inhibitors of farnesyl-protein transferase
US08/413137 1995-03-29
US08/413,137 US5578629A (en) 1995-03-29 1995-03-29 Benzamide-containing inhibitors of farnesyl-protein transferase
US08/412830 1995-03-29
PCT/US1996/003980 WO1996030015A1 (en) 1995-03-29 1996-03-25 Inhibitors of farnesyl-protein transferase

Publications (2)

Publication Number Publication Date
AU5370196A AU5370196A (en) 1996-10-16
AU706008B2 true AU706008B2 (en) 1999-06-03

Family

ID=27021935

Family Applications (1)

Application Number Title Priority Date Filing Date
AU53701/96A Ceased AU706008B2 (en) 1995-03-29 1996-03-25 Inhibitors of farnesyl-protein transferase

Country Status (5)

Country Link
EP (1) EP0817630A4 (en)
JP (1) JPH11503419A (en)
AU (1) AU706008B2 (en)
CA (1) CA2216564A1 (en)
WO (1) WO1996030015A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221865B1 (en) 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6310095B1 (en) 1995-11-06 2001-10-30 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6693123B2 (en) 1995-11-06 2004-02-17 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6204293B1 (en) 1995-11-06 2001-03-20 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
JP2000504014A (en) * 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド Farnesyl-protein transferase inhibitor
AU707416B2 (en) * 1996-04-03 1999-07-08 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507597A (en) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド Farnesyl protein transferase inhibitor
DE19613691A1 (en) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Medicines for the treatment of tumor diseases
WO1998050029A1 (en) * 1997-05-07 1998-11-12 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
FR2766819B1 (en) * 1997-07-31 1999-10-29 Pf Medicament NOVEL SUBSTITUTED ANILINE SULFONAMIDES USEFUL AS MEDICAMENTS
WO1999020612A1 (en) * 1997-10-22 1999-04-29 Astrazeneca Uk Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
WO1999020611A1 (en) * 1997-10-22 1999-04-29 Zeneca Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
WO2000039716A2 (en) * 1998-12-23 2000-07-06 Astrazeneca Ab Arylpropenylimidazoles as farnesyl-protein transferase inhibitors
GB9930318D0 (en) 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
HN2001000008A (en) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE
JP2008528604A (en) 2005-01-25 2008-07-31 グラクソ グループ リミテッド Antibacterial agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds

Also Published As

Publication number Publication date
JPH11503419A (en) 1999-03-26
AU5370196A (en) 1996-10-16
WO1996030015A1 (en) 1996-10-03
EP0817630A1 (en) 1998-01-14
CA2216564A1 (en) 1996-10-03
EP0817630A4 (en) 1999-01-27

Similar Documents

Publication Publication Date Title
US5578629A (en) Benzamide-containing inhibitors of farnesyl-protein transferase
US5534537A (en) Prodrugs of inhibitors of farnesyl-protein transferase
AU710481B2 (en) Inhibitors of farnesyl-protein transferase
AU704087B2 (en) Inhibitors of farnesyl-protein transferase
AU694572B2 (en) Inhibitors of farnesyl-protein transferase
US5869682A (en) Inhibitors of farnesyl-protein transferase
US5661161A (en) Inhibitors of farnesyl-protein transferase
AU706008B2 (en) Inhibitors of farnesyl-protein transferase
WO1997027852A1 (en) Inhibitors of farnesyl-protein transferase
AU712504B2 (en) Inhibitors of farnesyl-protein transferase
US5624936A (en) Inhibitors of farnesyl-protein transferase
US5571835A (en) Inhibitors of farnesyl-protein transferase
AU717298B2 (en) Inhibitors of farnesyl-protein transferase
WO1996034010A2 (en) Inhibitors of farnesyl-protein transferase
EP0783517A2 (en) Thiol-free inhibitors of farnesyl-protein transferase
US5627202A (en) Inhibitors of farnesyl-protein transferase
AU689651B2 (en) Inhibitors of farnesyl-protein transferase
AU703988B2 (en) Inhibitors of farnesyl-protein transferase
US5652257A (en) Heterocycle-containing inhibitors of farnesyl-protein transferase
AU708620B2 (en) Inhibitors of farnesyl-protein transferase
AU713698B2 (en) Inhibitors of farnesyl-protein transferase
WO1996031525A2 (en) Inhibitors of farnesyl-protein transferase
CA2243320A1 (en) Inhibitors of farnesyl-protein transferase
EP0837857A2 (en) Inhibitors of farnesyl-protein transferase
JPH11502822A (en) Farnesyl-protein transferase inhibitors

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired